{
  "doc_id": "30",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "磺脲类药物临床应用专家共识(2016年版)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物临床应用专家共识(2016年版)",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Expert consensus on the clinical application of sulfonylurea drugs (2016 edition)"
        }
      ],
      "paragraph_en": "Expert consensus on the clinical application of sulfonylurea drugs (2016 edition)"
    },
    {
      "paragraph_id": "2",
      "paragraph": "1 磺脲类药物的临床地位和使用时机",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1 磺脲类药物的临床地位和使用时机",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "1 Clinical status and timing of use of sulfonylureas"
        }
      ],
      "paragraph_en": "1 Clinical status and timing of use of sulfonylureas"
    },
    {
      "paragraph_id": "3",
      "paragraph": "1.1 国内外指南如何推荐使用磺脲类药物? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.1 国内外指南如何推荐使用磺脲类药物? ",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T2",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "1.1 How do domestic and international guidelines recommend the use of sulfonylureas?"
        }
      ],
      "paragraph_en": "1.1 How do domestic and international guidelines recommend the use of sulfonylureas?"
    },
    {
      "paragraph_id": "4",
      "paragraph": "尽管近年来新型降糖药物不断问世，但磺脲类药物因临床应用时间长、疗效确切，仍被多个国内外成人T2DM防治指南推荐为一线备选或二线降糖用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "尽管近年来新型降糖药物不断问世，但磺脲类药物因临床应用时间长、疗效确切，仍被多个国内外成人T2DM防治指南推荐为一线备选或二线降糖用药。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T3",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T4",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "T2"
            },
            {
              "entity_id": "T5",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "T2DM"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R0",
              "head_entity_id": "T3",
              "tail_entity_id": "T5"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R1",
              "head_entity_id": "T4",
              "tail_entity_id": "T5"
            }
          ],
          "sentence_en": "Although new glucose-lowering drugs have been continuously introduced in recent years, sulfonylureas are still recommended as first-line alternatives or second-line glucose-lowering drugs in many domestic and international guidelines for the prevention and treatment of adult T2DM due to their long clinical application time and definite efficacy."
        }
      ],
      "paragraph_en": "Although new glucose-lowering drugs have been continuously introduced in recent years, sulfonylureas are still recommended as first-line alternatives or second-line glucose-lowering drugs in many domestic and international guidelines for the prevention and treatment of adult T2DM due to their long clinical application time and definite efficacy."
    },
    {
      "paragraph_id": "6",
      "paragraph": "1.2 哪些情况下磺脲类药物可以作为治疗T2DM的一线选择?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.2 哪些情况下磺脲类药物可以作为治疗T2DM的一线选择?",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T6",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T7",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "T2"
            },
            {
              "entity_id": "T8",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "T2DM"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R2",
              "head_entity_id": "T7",
              "tail_entity_id": "T8"
            }
          ],
          "sentence_en": "1.2 In what cases can sulfonylureas be used as a first-line option for the treatment of T2DM?"
        }
      ],
      "paragraph_en": "1.2 In what cases can sulfonylureas be used as a first-line option for the treatment of T2DM?"
    },
    {
      "paragraph_id": "7",
      "paragraph": "中国大规模横断面调查研究发现，口服降糖药治疗仍是治疗T2DM的主要降糖方案。虽然二甲双胍被多数指南推荐为治疗T2DM的一线用药，但对于二甲双胍不耐受或存在禁忌证的患者，可以考虑将磺脲类药物作为一线用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国大规模横断面调查研究发现，口服降糖药治疗仍是治疗T2DM的主要降糖方案。虽然二甲双胍被多数指南推荐为治疗T2DM的一线用药，但对于二甲双胍不耐受或存在禁忌证的患者，可以考虑将磺脲类药物作为一线用药。",
          "start_idx": 0,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T9",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "oral"
            },
            {
              "entity_id": "T10",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T11",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T12",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 94,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T13",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "T2"
            },
            {
              "entity_id": "T14",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T15",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "T2"
            },
            {
              "entity_id": "T16",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "T2DM"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R3",
              "head_entity_id": "T11",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T13",
              "tail_entity_id": "T14"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R5",
              "head_entity_id": "T15",
              "tail_entity_id": "T16"
            }
          ],
          "sentence_en": "A large-scale cross-sectional survey in China found that oral hypoglycemic drugs are still the main glucose-lowering regimen for the treatment of T2DM. Although metformin is recommended as the first-line drug for the treatment of T2DM by most guidelines, sulfonylureas can be considered as the first-line drug for patients who are intolerant to metformin or have contraindications."
        }
      ],
      "paragraph_en": "A large-scale cross-sectional survey in China found that oral hypoglycemic drugs are still the main glucose-lowering regimen for the treatment of T2DM. Although metformin is recommended as the first-line drug for the treatment of T2DM by most guidelines, sulfonylureas can be considered as the first-line drug for patients who are intolerant to metformin or have contraindications."
    },
    {
      "paragraph_id": "8",
      "paragraph": "对于新诊断的糖化血红蛋白(hemoglobin A1c，HbA1c)>7.5%的T2DM患者，可以选择作用机制互补的两种降糖药物联合应用。结合中国国情和中国T2DM患者的特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于新诊断的糖化血红蛋白(hemoglobin A1c，HbA1c)>7.5%的T2DM患者，可以选择作用机制互补的两种降糖药物联合应用。结合中国国情和中国T2DM患者的特点，磺脲类药物联合二甲双胍是推荐的联合治疗方案之一。",
          "start_idx": 0,
          "end_idx": 112,
          "entities": [
            {
              "entity_id": "T17",
              "entity": "糖化血红蛋白(hemoglobin A1c，HbA1c)",
              "entity_type": "Test_items",
              "start_idx": 6,
              "end_idx": 34,
              "entity_en": "Glycated hemoglobin (HbA1c)"
            },
            {
              "entity_id": "T18",
              "entity": ">7.5%",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": ">7.5%"
            },
            {
              "entity_id": "T19",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 88,
              "end_idx": 93,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T20",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T21",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "T2"
            },
            {
              "entity_id": "T22",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T23",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 80,
              "entity_en": "T2"
            },
            {
              "entity_id": "T24",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "T2DM"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R6",
              "head_entity_id": "T17",
              "tail_entity_id": "T22"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R7",
              "head_entity_id": "T19",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R8",
              "head_entity_id": "T20",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R9",
              "head_entity_id": "T21",
              "tail_entity_id": "T22"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R10",
              "head_entity_id": "T23",
              "tail_entity_id": "T24"
            }
          ],
          "sentence_en": "For newly diagnosed T2DM patients with glycated hemoglobin A1c (HbA1c)>7.5%, two glucose-lowering drugs with complementary mechanisms of action can be used in combination. Considering China's national conditions and the characteristics of Chinese T2DM patients, sulfonylureas combined with metformin is one of the recommended combination treatment options."
        }
      ],
      "paragraph_en": "For newly diagnosed T2DM patients with glycated hemoglobin A1c (HbA1c) > 7.5%, two glucose-lowering drugs with complementary mechanisms of action can be used in combination. Considering China's national conditions and the characteristics of Chinese T2DM patients, sulfonylureas combined with metformin is one of the recommended combination treatment options."
    },
    {
      "paragraph_id": "9",
      "paragraph": "1.3 磺脲类药物可否用于超重或肥胖的T2DM患者? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.3 磺脲类药物可否用于超重或肥胖的T2DM患者? ",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T25",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T26",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T27",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T28",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "T2"
            },
            {
              "entity_id": "T29",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "T2DM"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R11",
              "head_entity_id": "T25",
              "tail_entity_id": "T29"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R12",
              "head_entity_id": "T28",
              "tail_entity_id": "T29"
            }
          ],
          "sentence_en": "1.3 Can sulfonylureas be used in overweight or obese patients with T2DM?"
        }
      ],
      "paragraph_en": "1.3 Can sulfonylureas be used in overweight or obese patients with T2DM?"
    },
    {
      "paragraph_id": "10",
      "paragraph": "磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。不同磺脲类药物单药治疗对患者体重的影响存在差异，改良剂型对患者体重的影响较小。临床研究显示，传统磺脲类药物(如氯磺丙脲、格列本脲)对肥胖患者体重影响较大，治疗3年平均约增加3~5kg；新的品种(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小(平均增加0.4~0.6kg)。由于二甲双胍、阿卡波糖、钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂等具有减轻体重的作用，对于超重或肥胖患者，磺脲类药物与此类药物联合使用，可减少磺脲类药物带来的体重增加的风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物可引起患者体重增加，但超重或肥胖并不是其治疗的禁忌证。不同磺脲类药物单药治疗对患者体重的影响存在差异，改良剂型对患者体重的影响较小。临床研究显示，传统磺脲类药物(如氯磺丙脲、格列本脲)对肥胖患者体重影响较大，治疗3年平均约增加3~5kg；新的品种(如格列美脲)和剂型(如格列齐特缓释片)对患者体重影响较小(平均增加0.4~0.6kg)。由于二甲双胍、阿卡波糖、钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂等具有减轻体重的作用，对于超重或肥胖患者，磺脲类药物与此类药物联合使用，可减少磺脲类药物带来的体重增加的风险。",
          "start_idx": 0,
          "end_idx": 295,
          "entities": [
            {
              "entity_id": "T30",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T31",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T32",
              "entity": "传统磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 85,
              "entity_en": "Traditional sulfonylurea drugs"
            },
            {
              "entity_id": "T33",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 87,
              "end_idx": 91,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T34",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 96,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T35",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T36",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 147,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T37",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 175,
              "end_idx": 179,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T38",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 184,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T39",
              "entity": "钠-葡萄糖协同转运蛋白2(sodium-glucose co-transporter 2，SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 185,
              "end_idx": 240,
              "entity_en": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors"
            },
            {
              "entity_id": "T40",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 261,
              "end_idx": 266,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T41",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 284,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T42",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T43",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T44",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 100,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T45",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 253,
              "end_idx": 255,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T46",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 256,
              "end_idx": 258,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T47",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T48",
              "entity": "减轻体重",
              "entity_type": "ADE",
              "start_idx": 243,
              "end_idx": 247,
              "entity_en": "Lose weight"
            },
            {
              "entity_id": "T49",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 287,
              "end_idx": 291,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R13",
              "head_entity_id": "T47",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R14",
              "head_entity_id": "T48",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R15",
              "head_entity_id": "T48",
              "tail_entity_id": "T38"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R16",
              "head_entity_id": "T48",
              "tail_entity_id": "T39"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R17",
              "head_entity_id": "T49",
              "tail_entity_id": "T41"
            }
          ],
          "sentence_en": "Sulfonylureas can cause patients to gain weight, but overweight or obesity is not a contraindication to their treatment. The effects of different sulfonylurea monotherapy on patients' weight vary, and the modified dosage form has less effect on patients' weight. Clinical studies have shown that traditional sulfonylureas (such as chlorpropamide and glibenclamide) have a greater impact on the weight of obese patients, with an average increase of about 3 to 5 kg after 3 years of treatment; new varieties (such as glimepiride) and dosage forms (such as gliclazide sustained-release tablets) have less effect on patients' weight (an average increase of 0.4 to 0.6 kg). Since metformin, acarbose, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, etc. have the effect of reducing weight, for overweight or obese patients, the combination of sulfonylureas and such drugs can reduce the risk of weight gain caused by sulfonylureas."
        }
      ],
      "paragraph_en": "Sulfonylureas can cause patients to gain weight, but overweight or obesity is not a contraindication to their treatment. The effects of different sulfonylurea monotherapy on patients' weight vary, and the modified dosage form has less effect on patients' weight. Clinical studies have shown that traditional sulfonylureas (such as chlorpropamide and glibenclamide) have a greater impact on the weight of obese patients, with an average increase of about 3 to 5 kg after 3 years of treatment; new varieties (such as glimepiride) and dosage forms (such as gliclazide sustained-release tablets) have less effect on patients' weight (an average increase of 0.4 to 0.6 kg). Since metformin, acarbose, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, etc. have the effect of reducing weight, for overweight or obese patients, the combination of sulfonylureas and such drugs can reduce the risk of weight gain caused by sulfonylureas."
    },
    {
      "paragraph_id": "11",
      "paragraph": "2 作用机制",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2 作用机制",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "2 Mechanism of action"
        }
      ],
      "paragraph_en": "2 Mechanism of action"
    },
    {
      "paragraph_id": "12",
      "paragraph": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，包括依赖KATP通道和不依赖KAT P通道刺激胰岛β细胞分泌胰岛素。格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。②部分胰岛素增敏作用。人体葡萄糖钳夹试验表明，磺脲类药物可使外周葡萄糖利用率增加10%~52%(平均29%)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，包括依赖KATP通道和不依赖KAT P通道刺激胰岛β细胞分泌胰岛素。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T50",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T51",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R18",
              "head_entity_id": "T50",
              "tail_entity_id": "T51"
            }
          ],
          "sentence_en": "The mechanisms by which sulfonylureas improve hyperglycemia include: ① stimulating pancreatic β cells to secrete insulin, including stimulating pancreatic β cells to secrete insulin by KATP channels and by channels that are independent of KATP channels."
        },
        {
          "sentence_id": "1",
          "sentence": "格列美脲可能具有葡萄糖依赖性的促胰岛素分泌作用。",
          "start_idx": 64,
          "end_idx": 88,
          "entities": [
            {
              "entity_id": "T52",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Glimepiride"
            }
          ],
          "relations": [],
          "sentence_en": "Glimepiride may have a glucose-dependent insulin secretion-stimulating effect."
        },
        {
          "sentence_id": "2",
          "sentence": "②部分胰岛素增敏作用。",
          "start_idx": 88,
          "end_idx": 99,
          "entities": [],
          "relations": [],
          "sentence_en": "②Partial insulin sensitizing effect."
        },
        {
          "sentence_id": "3",
          "sentence": "人体葡萄糖钳夹试验表明，磺脲类药物可使外周葡萄糖利用率增加10%~52%(平均29%)。",
          "start_idx": 99,
          "end_idx": 143,
          "entities": [
            {
              "entity_id": "T53",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Human glucose clamp tests have shown that sulfonylureas can increase peripheral glucose utilization by 10% to 52% (average 29%)."
        }
      ],
      "paragraph_en": "The mechanisms of sulfonylurea drugs in improving hyperglycemia include: ① stimulating pancreatic β cells to secrete insulin, including stimulating pancreatic β cells to secrete insulin by KATP channels and independently of KATP channels. Glimepiride may have a glucose-dependent insulin secretion-promoting effect. ② Partial insulin sensitization effect. Human glucose clamp tests have shown that sulfonylurea drugs can increase peripheral glucose utilization by 10% to 52% (average 29%)."
    },
    {
      "paragraph_id": "13",
      "paragraph": "3 临床疗效",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3 临床疗效",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "3 Clinical efficacy"
        }
      ],
      "paragraph_en": "3 Clinical efficacy"
    },
    {
      "paragraph_id": "14",
      "paragraph": "磺脲类药物单药治疗可使HbA1c下降1%~2%，降糖作用在常规剂量内呈剂量依赖性，且患者基线HbA1c越高，HbA1c降幅越大。磺脲类药物可以与多种其他降糖药物联合应用，并且可以作为治疗方案的基础用药之一长期使用。长期使用磺脲类药物治疗的患者应严密监测有无低血糖和体重增加。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物单药治疗可使HbA1c下降1%~2%，降糖作用在常规剂量内呈剂量依赖性，且患者基线HbA1c越高，HbA1c降幅越大。磺脲类药物可以与多种其他降糖药物联合应用，并且可以作为治疗方案的基础用药之一长期使用。长期使用磺脲类药物治疗的患者应严密监测有无低血糖和体重增加。",
          "start_idx": 0,
          "end_idx": 137,
          "entities": [
            {
              "entity_id": "T54",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T55",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 69,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T56",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T57",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T58",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 51,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T59",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 59,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T60",
              "entity": "下降1%~2%",
              "entity_type": "Test_Value",
              "start_idx": 16,
              "end_idx": 23,
              "entity_en": "Decrease by 1%~2%"
            },
            {
              "entity_id": "T61",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 128,
              "end_idx": 131,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T62",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 132,
              "end_idx": 136,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R19",
              "head_entity_id": "T61",
              "tail_entity_id": "T56"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R20",
              "head_entity_id": "T62",
              "tail_entity_id": "T56"
            }
          ],
          "sentence_en": "Sulfonylurea monotherapy can reduce HbA1c by 1% to 2%. The hypoglycemic effect is dose-dependent within the conventional dose, and the higher the patient's baseline HbA1c, the greater the reduction in HbA1c. Sulfonylureas can be used in combination with a variety of other hypoglycemic drugs and can be used as one of the basic drugs in the treatment plan for a long time. Patients who use sulfonylureas for a long time should be closely monitored for hypoglycemia and weight gain."
        }
      ],
      "paragraph_en": "Sulfonylurea monotherapy can reduce HbA1c by 1% to 2%. The hypoglycemic effect is dose-dependent within the conventional dose, and the higher the patient's baseline HbA1c, the greater the reduction in HbA1c. Sulfonylureas can be used in combination with a variety of other hypoglycemic drugs and can be used as one of the basic drugs in the treatment plan for a long time. Patients who use sulfonylureas for a long time should be closely monitored for hypoglycemia and weight gain."
    },
    {
      "paragraph_id": "15",
      "paragraph": "应用磺脲类药物治疗的患者需要有一定的胰岛功能。糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物治疗可能具有更好的疗效。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "应用磺脲类药物治疗的患者需要有一定的胰岛功能。糖尿病病程较短且能够坚持饮食和运动干预的患者使用磺脲类药物治疗可能具有更好的疗效。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T63",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T64",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T65",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T66",
              "entity": "饮食和运动干预",
              "entity_type": "Treatment",
              "start_idx": 35,
              "end_idx": 42,
              "entity_en": "Diet and exercise interventions"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R21",
              "head_entity_id": "T65",
              "tail_entity_id": "T64"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R22",
              "head_entity_id": "T66",
              "tail_entity_id": "T64"
            }
          ],
          "sentence_en": "Patients treated with sulfonylureas need to have a certain level of pancreatic islet function. Patients with a shorter course of diabetes and who can adhere to diet and exercise interventions may have better efficacy with sulfonylureas."
        }
      ],
      "paragraph_en": "Patients treated with sulfonylureas need to have a certain level of pancreatic islet function. Patients with a shorter course of diabetes and who can adhere to diet and exercise interventions may have better efficacy with sulfonylureas."
    },
    {
      "paragraph_id": "16",
      "paragraph": "3.1 目前常用的磺脲类药物有哪些?如何调整剂量? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.1 目前常用的磺脲类药物有哪些?如何调整剂量? ",
          "start_idx": 0,
          "end_idx": 26,
          "entities": [
            {
              "entity_id": "T67",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "3.1 What are the commonly used sulfonylurea drugs? How to adjust the dosage?"
        }
      ],
      "paragraph_en": "3.1 What are the commonly used sulfonylurea drugs? How to adjust the dosage?"
    },
    {
      "paragraph_id": "17",
      "paragraph": "早期的磺脲类药物以甲苯磺丁脲和氯磺丙脲为代表，由于甲苯磺丁脲增加T2DM患者心血管事件的发生风险，氯磺丙脲作用时间过长易导致低血糖等原因，临床上已基本淘汰。新一代磺脲类药物具有降糖作用强、不良反应少等优势，包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲(易导致低血糖临床较少使用)等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "早期的磺脲类药物以甲苯磺丁脲和氯磺丙脲为代表，由于甲苯磺丁脲增加T2DM患者心血管事件的发生风险，氯磺丙脲作用时间过长易导致低血糖等原因，临床上已基本淘汰。新一代磺脲类药物具有降糖作用强、不良反应少等优势，包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲(易导致低血糖临床较少使用)等。",
          "start_idx": 0,
          "end_idx": 145,
          "entities": [
            {
              "entity_id": "T68",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T69",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Tolbutamide"
            },
            {
              "entity_id": "T70",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T71",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 30,
              "entity_en": "Tolbutamide"
            },
            {
              "entity_id": "T72",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T73",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 81,
              "end_idx": 86,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T74",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 105,
              "end_idx": 109,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T75",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 110,
              "end_idx": 114,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T76",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 119,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T77",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 124,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T78",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 129,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T79",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "T2"
            },
            {
              "entity_id": "T80",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T81",
              "entity": "心血管事件",
              "entity_type": "ADE",
              "start_idx": 38,
              "end_idx": 43,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T82",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 62,
              "end_idx": 65,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T83",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 133,
              "end_idx": 136,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R23",
              "head_entity_id": "T68",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R24",
              "head_entity_id": "T69",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T70",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R26",
              "head_entity_id": "T71",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R27",
              "head_entity_id": "T81",
              "tail_entity_id": "T71"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R28",
              "head_entity_id": "T82",
              "tail_entity_id": "T72"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R29",
              "head_entity_id": "T83",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R30",
              "head_entity_id": "T83",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R31",
              "head_entity_id": "T83",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R32",
              "head_entity_id": "T83",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R33",
              "head_entity_id": "T83",
              "tail_entity_id": "T78"
            }
          ],
          "sentence_en": "Early sulfonylurea drugs were represented by tolbutamide and chlorpropamide. Since tolbutamide increases the risk of cardiovascular events in patients with T2DM and chlorpropamide has a long duration of action and can easily lead to hypoglycemia, they have been basically eliminated in clinical practice. The new generation of sulfonylurea drugs have the advantages of strong hypoglycemic effect and few adverse reactions, including glimepiride, gliclazide, glipizide, gliquidone, and glibenclamide (which is less used in clinical practice because it can easily lead to hypoglycemia)."
        }
      ],
      "paragraph_en": "Early sulfonylurea drugs were represented by tolbutamide and chlorpropamide. Since tolbutamide increases the risk of cardiovascular events in patients with T2DM and chlorpropamide has a long duration of action and can easily lead to hypoglycemia, they have been basically eliminated in clinical practice. The new generation of sulfonylurea drugs have the advantages of strong hypoglycemic effect and few adverse reactions, including glimepiride, gliclazide, glipizide, gliquidone, and glibenclamide (which is less used in clinical practice because it can easily lead to hypoglycemia)."
    },
    {
      "paragraph_id": "18",
      "paragraph": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长。短效药物需要每日3次给药，中、长效药物每日给药1~2次即可。以餐后血糖升高为主的患者，宜选择短效制剂，以空腹血糖升高为主的患者或空腹、餐后血糖均高者，宜选择中、长效制剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列喹酮、格列吡嗪普通剂型属于短效制剂，作用时间较短；格列美脲、格列吡嗪控释剂、格列齐特、格列齐特缓释片、格列本脲为中、长效制剂，作用时间较长。短效药物需要每日3次给药，中、长效药物每日给药1~2次即可。",
          "start_idx": 0,
          "end_idx": 102,
          "entities": [
            {
              "entity_id": "T84",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T85",
              "entity": "格列吡嗪普通剂型",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 13,
              "entity_en": "Glipizide common dosage form"
            },
            {
              "entity_id": "T86",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T87",
              "entity": "格列吡嗪控释剂",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 39,
              "entity_en": "Glipizide controlled release"
            },
            {
              "entity_id": "T88",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T89",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 52,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T90",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T91",
              "entity": "每日3次",
              "entity_type": "Frequency",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "3 times a day"
            },
            {
              "entity_id": "T92",
              "entity": "每日给药1~2次",
              "entity_type": "Frequency",
              "start_idx": 91,
              "end_idx": 99,
              "entity_en": "Take 1 to 2 times a day"
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R34",
              "head_entity_id": "T91",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R35",
              "head_entity_id": "T91",
              "tail_entity_id": "T85"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R36",
              "head_entity_id": "T92",
              "tail_entity_id": "T86"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R37",
              "head_entity_id": "T92",
              "tail_entity_id": "T87"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R38",
              "head_entity_id": "T92",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R39",
              "head_entity_id": "T92",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R40",
              "head_entity_id": "T92",
              "tail_entity_id": "T90"
            }
          ],
          "sentence_en": "Gliquidone and glipizide are short-acting preparations with a short duration of action; glimepiride, glipizide controlled-release, gliclazide, gliclazide sustained-release tablets, and glibenclamide are medium- and long-acting preparations with a longer duration of action. Short-acting drugs need to be administered three times a day, while medium- and long-acting drugs can be administered 1 to 2 times a day."
        },
        {
          "sentence_id": "1",
          "sentence": "以餐后血糖升高为主的患者，宜选择短效制剂，以空腹血糖升高为主的患者或空腹、餐后血糖均高者，宜选择中、长效制剂。",
          "start_idx": 102,
          "end_idx": 157,
          "entities": [
            {
              "entity_id": "T93",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T94",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Fasting blood sugar"
            },
            {
              "entity_id": "T95",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T96",
              "entity": "空腹、餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 41,
              "entity_en": "Fasting and postprandial blood sugar"
            },
            {
              "entity_id": "T97",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T98",
              "entity": "均高",
              "entity_type": "Test_Value",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "Average height"
            }
          ],
          "relations": [],
          "sentence_en": "For patients with mainly elevated postprandial blood sugar, short-acting preparations should be selected. For patients with mainly elevated fasting blood sugar or those with high fasting and postprandial blood sugar, medium- or long-acting preparations should be selected."
        }
      ],
      "paragraph_en": "Gliquidone and glipizide are short-acting preparations with a short duration of action; glimepiride, glipizide controlled-release, gliclazide, gliclazide sustained-release tablets, and glibenclamide are medium- and long-acting preparations with a longer duration of action. Short-acting drugs need to be administered three times a day, while medium- and long-acting drugs can be administered 1 to 2 times a day. Patients with mainly elevated postprandial blood sugar should choose short-acting preparations, while patients with mainly elevated fasting blood sugar or those with high fasting and postprandial blood sugar should choose medium- and long-acting preparations."
    },
    {
      "paragraph_id": "19",
      "paragraph": "低血糖是磺脲类药物治疗最常见的不良反应。为减少低血糖风险，服用磺脲类药物时宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。任何一种磺脲类药物的每日用量不应超过其最大剂量。常用磺脲类药物的用法、用量见表2。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "低血糖是磺脲类药物治疗最常见的不良反应。为减少低血糖风险，服用磺脲类药物时宜从小剂量开始，根据血糖监测结果逐渐调整用量，一般每1~2周调整一次。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T99",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T100",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T103",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T104",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T105",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R41",
              "head_entity_id": "T103",
              "tail_entity_id": "T99"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R42",
              "head_entity_id": "T104",
              "tail_entity_id": "T100"
            }
          ],
          "sentence_en": "Hypoglycemia is the most common adverse reaction to sulfonylurea therapy. To reduce the risk of hypoglycemia, it is advisable to start with a low dose when taking sulfonylureas and gradually adjust the dosage based on blood sugar monitoring results, generally every 1 to 2 weeks."
        },
        {
          "sentence_id": "1",
          "sentence": "任何一种磺脲类药物的每日用量不应超过其最大剂量。",
          "start_idx": 72,
          "end_idx": 96,
          "entities": [
            {
              "entity_id": "T101",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "The daily dose of any sulfonylurea should not exceed its maximum dose."
        },
        {
          "sentence_id": "2",
          "sentence": "常用磺脲类药物的用法、用量见表2。",
          "start_idx": 96,
          "end_idx": 113,
          "entities": [
            {
              "entity_id": "T102",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "The usage and dosage of commonly used sulfonylurea drugs are shown in Table 2."
        }
      ],
      "paragraph_en": "Hypoglycemia is the most common adverse reaction to sulfonylurea therapy. To reduce the risk of hypoglycemia, it is advisable to start with a low dose when taking sulfonylureas and gradually adjust the dosage according to the results of blood glucose monitoring, generally every 1 to 2 weeks. The daily dosage of any sulfonylurea should not exceed its maximum dose. The usage and dosage of commonly used sulfonylureas are shown in Table 2."
    },
    {
      "paragraph_id": "20",
      "paragraph": "3.2 磺脲类药物单药治疗疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.2 磺脲类药物单药治疗疗效如何? ",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T106",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "3.2 What is the efficacy of sulfonylurea monotherapy?"
        }
      ],
      "paragraph_en": "3.2 What is the efficacy of sulfonylurea monotherapy?"
    },
    {
      "paragraph_id": "21",
      "paragraph": "磺脲类药物单药治疗一般可降低HbA1c1%~2%，平均降低1.5%。对于新诊断T2DM患者，格列齐特缓释片单药治疗52周可使HbA1c降低1.28%，安全性良好，治疗期间无严重低血糖事件发生；格列吡嗪控释片单药治疗8周可使HbA1c降低1.12%；格列本脲单药治疗12个月可使HbA1c降低1.26%；格列美脲单药治疗16周可使HbA1c降低2.5%，稳态模型评估的β细胞功能指数(HOMA-β)显著升高，稳态模型评估的胰岛素抵抗指数(HOMA-IR)显著降低，经血糖检测≤3.9mmol/L证实的低血糖发生率为3.8%，总体安全性良好。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物单药治疗一般可降低HbA1c1%~2%，平均降低1.5%。对于新诊断T2DM患者，格列齐特缓释片单药治疗52周可使HbA1c降低1.28%，安全性良好，治疗期间无严重低血糖事件发生；格列吡嗪控释片单药治疗8周可使HbA1c降低1.12%；格列本脲单药治疗12个月可使HbA1c降低1.26%；格列美脲单药治疗16周可使HbA1c降低2.5%，稳态模型评估的β细胞功能指数(HOMA-β)显著升高，稳态模型评估的胰岛素抵抗指数(HOMA-IR)显著降低，经血糖检测≤3.9mmol/L证实的低血糖发生率为3.8%，总体安全性良好。",
          "start_idx": 0,
          "end_idx": 269,
          "entities": [
            {
              "entity_id": "T107",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T108",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 53,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T109",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 103,
              "entity_en": "Glipizide Extended Release Tablets"
            },
            {
              "entity_id": "T110",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T111",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 155,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T112",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T113",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T114",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T115",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 138,
              "end_idx": 143,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T116",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 164,
              "end_idx": 169,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T117",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 232,
              "end_idx": 234,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T118",
              "entity": "1%~2%",
              "entity_type": "Test_Value",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "1%~2%"
            },
            {
              "entity_id": "T119",
              "entity": "降低1.5%",
              "entity_type": "Test_Value",
              "start_idx": 27,
              "end_idx": 33,
              "entity_en": "1.5% reduction"
            },
            {
              "entity_id": "T120",
              "entity": "降低1.28%",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 74,
              "entity_en": "1.28% reduction"
            },
            {
              "entity_id": "T121",
              "entity": "降低1.12%",
              "entity_type": "Test_Value",
              "start_idx": 116,
              "end_idx": 123,
              "entity_en": "Decrease by 1.12%"
            },
            {
              "entity_id": "T122",
              "entity": "降低1.26%",
              "entity_type": "Test_Value",
              "start_idx": 143,
              "end_idx": 150,
              "entity_en": "Decrease by 1.26%"
            },
            {
              "entity_id": "T123",
              "entity": "降低2.5%",
              "entity_type": "Test_Value",
              "start_idx": 169,
              "end_idx": 175,
              "entity_en": "2.5% reduction"
            },
            {
              "entity_id": "T124",
              "entity": "≤3.9mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 236,
              "end_idx": 246,
              "entity_en": "≤3.9mmol/L"
            },
            {
              "entity_id": "T125",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "T2"
            },
            {
              "entity_id": "T126",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T127",
              "entity": "52周",
              "entity_type": "Duration",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "52 weeks"
            },
            {
              "entity_id": "T128",
              "entity": "8周",
              "entity_type": "Duration",
              "start_idx": 107,
              "end_idx": 109,
              "entity_en": "8 weeks"
            },
            {
              "entity_id": "T129",
              "entity": "12个月",
              "entity_type": "Duration",
              "start_idx": 132,
              "end_idx": 136,
              "entity_en": "12 months"
            },
            {
              "entity_id": "T130",
              "entity": "16周",
              "entity_type": "Duration",
              "start_idx": 159,
              "end_idx": 162,
              "entity_en": "16 weeks"
            },
            {
              "entity_id": "T131",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T132",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "serious"
            },
            {
              "entity_id": "T133",
              "entity": "β细胞功能指数(HOMA-β)",
              "entity_type": "Test_items",
              "start_idx": 183,
              "end_idx": 198,
              "entity_en": "β-cell function index (HOMA-β)"
            },
            {
              "entity_id": "T134",
              "entity": "显著升高",
              "entity_type": "Test_Value",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "Significantly increased"
            },
            {
              "entity_id": "T135",
              "entity": "胰岛素抵抗指数(HOMA-IR)",
              "entity_type": "Test_items",
              "start_idx": 210,
              "end_idx": 226,
              "entity_en": "Insulin resistance index (HOMA-IR)"
            },
            {
              "entity_id": "T136",
              "entity": "显著降低",
              "entity_type": "Test_Value",
              "start_idx": 226,
              "end_idx": 230,
              "entity_en": "Significantly reduce"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R43",
              "head_entity_id": "T108",
              "tail_entity_id": "T126"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R44",
              "head_entity_id": "T131",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R45",
              "head_entity_id": "T127",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R46",
              "head_entity_id": "T128",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R47",
              "head_entity_id": "T129",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R48",
              "head_entity_id": "T130",
              "tail_entity_id": "T111"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R49",
              "head_entity_id": "T125",
              "tail_entity_id": "T126"
            }
          ],
          "sentence_en": "Sulfonylurea monotherapy can generally reduce HbA1c by 1%~2%, with an average reduction of 1.5%. For newly diagnosed T2DM patients, gliclazide extended-release tablet monotherapy for 52 weeks can reduce HbA1c by 1.28%, with good safety, and no severe hypoglycemia events occurred during treatment; glipizide controlled-release tablet monotherapy for 8 weeks can reduce HbA1c by 1.12%; glibenclamide monotherapy for 12 months can reduce HbA1c by 1.26%; glimepiride monotherapy for 16 weeks can reduce HbA1c by 2.5%, the homeostasis model assessment of β-cell function index (HOMA-β) is significantly increased, the homeostasis model assessment of insulin resistance index (HOMA-IR) is significantly reduced, and the incidence of hypoglycemia confirmed by blood glucose test ≤3.9mmol/L is 3.8%, with good overall safety."
        }
      ],
      "paragraph_en": "Sulfonylurea monotherapy can generally reduce HbA1c by 1%~2%, with an average reduction of 1.5%. For newly diagnosed T2DM patients, gliclazide extended-release tablet monotherapy for 52 weeks can reduce HbA1c by 1.28%, with good safety, and no severe hypoglycemia events occurred during treatment; glipizide controlled-release tablet monotherapy for 8 weeks can reduce HbA1c by 1.12%; glibenclamide monotherapy for 12 months can reduce HbA1c by 1.26%; glimepiride monotherapy for 16 weeks can reduce HbA1c by 2.5%, the homeostasis model assessment of β-cell function index (HOMA-β) is significantly increased, the homeostasis model assessment of insulin resistance index (HOMA-IR) is significantly reduced, and the incidence of hypoglycemia confirmed by blood glucose testing ≤3.9mmol/L is 3.8%, with good overall safety."
    },
    {
      "paragraph_id": "22",
      "paragraph": "3.3 磺脲类药物联合二甲双胍疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.3 磺脲类药物联合二甲双胍疗效如何? ",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T137",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T138",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "3.3 What is the efficacy of sulfonylureas combined with metformin?"
        }
      ],
      "paragraph_en": "3.3 What is the efficacy of sulfonylureas combined with metformin?"
    },
    {
      "paragraph_id": "23",
      "paragraph": "磺脲类药物与二甲双胍联合治疗可同时改善胰岛素分泌不足和胰岛素抵抗，其疗效和安全性已得到长期临床验证，是推荐的联合治疗方案之一。一项系统性评价结果显示，磺脲类药物联合二甲双胍可使HbA1c降低0.47%~1.30%。与二甲双胍单药治疗相比，二甲双胍联合格列齐特或格列美脲治疗3个月均可使患者HbA1c降低1.9%。为期2年的随机对照研究结果显示，T2DM患者起始二甲双胍联合磺脲类药物治疗可降低HbA1c 1.5%；二甲双胍单药治疗血糖控制不佳的患者加用格列吡嗪治疗可使HbA1c进一步降低0.59%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物与二甲双胍联合治疗可同时改善胰岛素分泌不足和胰岛素抵抗，其疗效和安全性已得到长期临床验证，是推荐的联合治疗方案之一。一项系统性评价结果显示，磺脲类药物联合二甲双胍可使HbA1c降低0.47%~1.30%。与二甲双胍单药治疗相比，二甲双胍联合格列齐特或格列美脲治疗3个月均可使患者HbA1c降低1.9%。为期2年的随机对照研究结果显示，T2DM患者起始二甲双胍联合磺脲类药物治疗可降低HbA1c 1.5%；二甲双胍单药治疗血糖控制不佳的患者加用格列吡嗪治疗可使HbA1c进一步降低0.59%。",
          "start_idx": 0,
          "end_idx": 250,
          "entities": [
            {
              "entity_id": "T139",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T140",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T141",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 80,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T142",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 82,
              "end_idx": 86,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T143",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 112,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T144",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T145",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 129,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T146",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T147",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 184,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T148",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 186,
              "end_idx": 191,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T149",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 211,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T150",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 226,
              "end_idx": 230,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T151",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 93,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T152",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 144,
              "end_idx": 149,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T153",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 196,
              "end_idx": 201,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T154",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 234,
              "end_idx": 239,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T155",
              "entity": "降低0.47%~1.30%",
              "entity_type": "Test_Value",
              "start_idx": 93,
              "end_idx": 106,
              "entity_en": "Reduced by 0.47%~1.30%"
            },
            {
              "entity_id": "T156",
              "entity": "降低1.9%",
              "entity_type": "Test_Value",
              "start_idx": 149,
              "end_idx": 155,
              "entity_en": "1.9% decrease"
            },
            {
              "entity_id": "T157",
              "entity": "1.5%",
              "entity_type": "Test_Value",
              "start_idx": 202,
              "end_idx": 206,
              "entity_en": "1.5%"
            },
            {
              "entity_id": "T158",
              "entity": "降低0.59%",
              "entity_type": "Test_Value",
              "start_idx": 242,
              "end_idx": 249,
              "entity_en": "Decrease by 0.59%"
            },
            {
              "entity_id": "T159",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 172,
              "end_idx": 174,
              "entity_en": "T2"
            },
            {
              "entity_id": "T160",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 172,
              "end_idx": 176,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T161",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 215,
              "end_idx": 217,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T162",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 217,
              "end_idx": 221,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T163",
              "entity": "胰岛素分泌不足",
              "entity_type": "Pathogenesis",
              "start_idx": 19,
              "end_idx": 26,
              "entity_en": "Insufficient insulin secretion"
            },
            {
              "entity_id": "T164",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Insulin resistance"
            },
            {
              "entity_id": "T165",
              "entity": "3个月",
              "entity_type": "Duration",
              "start_idx": 136,
              "end_idx": 139,
              "entity_en": "3 months"
            }
          ],
          "relations": [
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R50",
              "head_entity_id": "T165",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R51",
              "head_entity_id": "T165",
              "tail_entity_id": "T145"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R52",
              "head_entity_id": "T165",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T147",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T148",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R55",
              "head_entity_id": "T159",
              "tail_entity_id": "T160"
            }
          ],
          "sentence_en": "Sulfonylurea combined with metformin can improve both insufficient insulin secretion and insulin resistance. Its efficacy and safety have been verified in long-term clinical practice and it is one of the recommended combined treatment options. A systematic review showed that sulfonylurea combined with metformin can reduce HbA1c by 0.47% to 1.30%. Compared with metformin monotherapy, metformin combined with gliclazide or glimepiride can reduce patients' HbA1c by 1.9% after 3 months of treatment. The results of a 2-year randomized controlled study showed that T2DM patients who started metformin combined with sulfonylurea treatment could reduce HbA1c by 1.5%; patients with poor blood sugar control on metformin monotherapy could further reduce HbA1c by 0.59% by adding glipizide."
        }
      ],
      "paragraph_en": "Sulfonylurea combined with metformin can improve both insufficient insulin secretion and insulin resistance. Its efficacy and safety have been verified in long-term clinical practice and it is one of the recommended combined treatment options. A systematic review showed that sulfonylurea combined with metformin can reduce HbA1c by 0.47% to 1.30%. Compared with metformin monotherapy, metformin combined with gliclazide or glimepiride can reduce patients' HbA1c by 1.9% after 3 months of treatment. The results of a 2-year randomized controlled study showed that T2DM patients who started metformin combined with sulfonylurea treatment could reduce HbA1c by 1.5%; patients with poor blood sugar control on metformin monotherapy could further reduce HbA1c by 0.59% by adding glipizide."
    },
    {
      "paragraph_id": "24",
      "paragraph": "3.4 磺脲类药物联合α-糖苷酶抑制剂的疗效如何?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.4 磺脲类药物联合α-糖苷酶抑制剂的疗效如何?",
          "start_idx": 0,
          "end_idx": 25,
          "entities": [
            {
              "entity_id": "T166",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T167",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 19,
              "entity_en": "α-Glucosidase inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "3.4 What is the efficacy of sulfonylureas combined with α-glucosidase inhibitors?"
        }
      ],
      "paragraph_en": "3.4 What is the efficacy of sulfonylureas combined with α-glucosidase inhibitors?"
    },
    {
      "paragraph_id": "25",
      "paragraph": "磺脲类药物促进胰岛素分泌，α-糖苷酶抑制剂抑制肠道碳水化合物吸收，二者联合，机制互补，可更好地控制T2DM患者的空腹血糖和餐后血糖。一项交叉设计临床对照研究，磺脲类药物联合阿卡波糖可使患者HbA1c下降2.2%，空腹血糖(fasting plasma glucose，FPG)下降2.8mmol/L，餐后血糖(postprandial plasma glucose，PPG)下降5.3mmol/L，甘油三酯下降35.7mg/dl。随机、双盲、安慰剂对照研究显示，与阿卡波糖、格列本脲单药治疗相比，格列本脲联合阿卡波糖可显著降低患者的餐后血糖，且较格列本脲单药治疗显著降低患者血清胰岛素水平。对于新诊断T2DM患者，格列吡嗪控释片联合阿卡波糖治疗8周较格列吡嗪控释片单药治疗，患者的体质指数(body mass index，BMI)、腰围及HbA1c变化无统计学差异，但前者可显著改善患者HOMA-IR，降低餐后血糖增量，且有效减少血糖波动(日间血糖变异度与日内血糖变异度)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物促进胰岛素分泌，α-糖苷酶抑制剂抑制肠道碳水化合物吸收，二者联合，机制互补，可更好地控制T2DM患者的空腹血糖和餐后血糖。一项交叉设计临床对照研究，磺脲类药物联合阿卡波糖可使患者HbA1c下降2.2%，空腹血糖(fasting plasma glucose，FPG)下降2.8mmol/L，餐后血糖(postprandial plasma glucose，PPG)下降5.3mmol/L，甘油三酯下降35.7mg/dl。随机、双盲、安慰剂对照研究显示，与阿卡波糖、格列本脲单药治疗相比，格列本脲联合阿卡波糖可显著降低患者的餐后血糖，且较格列本脲单药治疗显著降低患者血清胰岛素水平。对于新诊断T2DM患者，格列吡嗪控释片联合阿卡波糖治疗8周较格列吡嗪控释片单药治疗，患者的体质指数(body mass index，BMI)、腰围及HbA1c变化无统计学差异，但前者可显著改善患者HOMA-IR，降低餐后血糖增量，且有效减少血糖波动(日间血糖变异度与日内血糖变异度)。",
          "start_idx": 0,
          "end_idx": 437,
          "entities": [
            {
              "entity_id": "T168",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T169",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 21,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T170",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 84,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T171",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 90,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T172",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 232,
              "end_idx": 236,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T173",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 237,
              "end_idx": 241,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T174",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 248,
              "end_idx": 252,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T175",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 254,
              "end_idx": 258,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T176",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 273,
              "end_idx": 277,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T177",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 307,
              "end_idx": 314,
              "entity_en": "Glipizide Extended Release Tablets"
            },
            {
              "entity_id": "T178",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 316,
              "end_idx": 320,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T179",
              "entity": "格列吡嗪控释片",
              "entity_type": "Drug",
              "start_idx": 325,
              "end_idx": 332,
              "entity_en": "Glipizide Extended Release Tablets"
            },
            {
              "entity_id": "T180",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "T2"
            },
            {
              "entity_id": "T181",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T182",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 56,
              "end_idx": 60,
              "entity_en": "Fasting blood sugar"
            },
            {
              "entity_id": "T183",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T184",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 94,
              "end_idx": 99,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T185",
              "entity": "空腹血糖(fasting plasma glucose，FPG)",
              "entity_type": "Test_items",
              "start_idx": 106,
              "end_idx": 138,
              "entity_en": "Fasting plasma glucose (FPG)"
            },
            {
              "entity_id": "T186",
              "entity": "餐后血糖(postprandial plasma glucose，PPG)",
              "entity_type": "Test_items",
              "start_idx": 150,
              "end_idx": 187,
              "entity_en": "Postprandial plasma glucose (PPG)"
            },
            {
              "entity_id": "T187",
              "entity": "甘油三酯",
              "entity_type": "Test_items",
              "start_idx": 199,
              "end_idx": 203,
              "entity_en": "Triglycerides"
            },
            {
              "entity_id": "T188",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 266,
              "end_idx": 270,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T189",
              "entity": "血清胰岛素水平",
              "entity_type": "Test_items",
              "start_idx": 287,
              "end_idx": 294,
              "entity_en": "Serum insulin levels"
            },
            {
              "entity_id": "T190",
              "entity": "体质指数(body mass index，BMI)",
              "entity_type": "Test_items",
              "start_idx": 340,
              "end_idx": 365,
              "entity_en": "Body mass index (BMI)"
            },
            {
              "entity_id": "T191",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 369,
              "end_idx": 374,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T192",
              "entity": "HOMA-IR",
              "entity_type": "Test_items",
              "start_idx": 393,
              "end_idx": 400,
              "entity_en": "HOMA-IR"
            },
            {
              "entity_id": "T193",
              "entity": "餐后血糖增量",
              "entity_type": "Test_items",
              "start_idx": 403,
              "end_idx": 409,
              "entity_en": "Postprandial blood sugar increase"
            },
            {
              "entity_id": "T194",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 415,
              "end_idx": 417,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T195",
              "entity": "日间血糖变异度",
              "entity_type": "Test_items",
              "start_idx": 420,
              "end_idx": 427,
              "entity_en": "Daily blood sugar variability"
            },
            {
              "entity_id": "T196",
              "entity": "日内血糖变异度",
              "entity_type": "Test_items",
              "start_idx": 428,
              "end_idx": 435,
              "entity_en": "Intraday blood glucose variability"
            },
            {
              "entity_id": "T197",
              "entity": "下降2.2%",
              "entity_type": "Test_Value",
              "start_idx": 99,
              "end_idx": 105,
              "entity_en": "Down 2.2%"
            },
            {
              "entity_id": "T198",
              "entity": "下降2.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 138,
              "end_idx": 149,
              "entity_en": "Decreased by 2.8mmol/L"
            },
            {
              "entity_id": "T199",
              "entity": "下降5.3mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 187,
              "end_idx": 198,
              "entity_en": "Decreased by 5.3mmol/L"
            },
            {
              "entity_id": "T200",
              "entity": "下降35.7mg/dl",
              "entity_type": "Test_Value",
              "start_idx": 203,
              "end_idx": 214,
              "entity_en": "Decreased by 35.7 mg/dl"
            },
            {
              "entity_id": "T201",
              "entity": "8周",
              "entity_type": "Duration",
              "start_idx": 322,
              "end_idx": 324,
              "entity_en": "8 weeks"
            },
            {
              "entity_id": "T202",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 300,
              "end_idx": 302,
              "entity_en": "T2"
            },
            {
              "entity_id": "T203",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 300,
              "end_idx": 304,
              "entity_en": "T2DM"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R56",
              "head_entity_id": "T168",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R57",
              "head_entity_id": "T169",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T177",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R59",
              "head_entity_id": "T201",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R60",
              "head_entity_id": "T178",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R61",
              "head_entity_id": "T201",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R62",
              "head_entity_id": "T180",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R63",
              "head_entity_id": "T182",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R64",
              "head_entity_id": "T183",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R65",
              "head_entity_id": "T190",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R66",
              "head_entity_id": "T191",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R67",
              "head_entity_id": "T192",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R68",
              "head_entity_id": "T193",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R69",
              "head_entity_id": "T194",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R70",
              "head_entity_id": "T195",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R71",
              "head_entity_id": "T196",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R72",
              "head_entity_id": "T202",
              "tail_entity_id": "T203"
            }
          ],
          "sentence_en": "Sulfonylureas promote insulin secretion, and α-glucosidase inhibitors inhibit intestinal carbohydrate absorption. The combination of the two has complementary mechanisms and can better control fasting blood glucose and postprandial blood glucose in patients with T2DM. In a cross-design clinical controlled study, sulfonylureas combined with acarbose can reduce patients' HbA1c by 2.2%, fasting plasma glucose (FPG) by 2.8mmol/L, postprandial plasma glucose (PPG) by 5.3mmol/L, and triglycerides by 35.7mg/dl. Randomized, double-blind, placebo-controlled studies have shown that compared with acarbose and glibenclamide monotherapy, glibenclamide combined with acarbose can significantly reduce patients' postprandial blood glucose, and significantly reduce patients' serum insulin levels compared with glibenclamide monotherapy. For newly diagnosed T2DM patients, there was no statistical difference in body mass index (BMI), waist circumference and HbA1c between 8 weeks of treatment with glipizide controlled-release tablets combined with acarbose and glipizide controlled-release tablets alone. However, the former could significantly improve patients' HOMA-IR, reduce postprandial blood glucose increment, and effectively reduce blood glucose fluctuations (inter-day blood glucose variability and intra-day blood glucose variability)."
        }
      ],
      "paragraph_en": "Sulfonylureas promote insulin secretion, and α-glucosidase inhibitors inhibit intestinal carbohydrate absorption. The combination of the two has complementary mechanisms and can better control fasting blood glucose and postprandial blood glucose in patients with T2DM. In a cross-design clinical controlled study, sulfonylureas combined with acarbose can reduce patients' HbA1c by 2.2%, fasting plasma glucose (FPG) by 2.8mmol/L, postprandial plasma glucose (PPG) by 5.3mmol/L, and triglycerides by 35.7mg/dl. Randomized, double-blind, placebo-controlled studies have shown that compared with acarbose and glibenclamide monotherapy, glibenclamide combined with acarbose can significantly reduce patients' postprandial blood glucose, and significantly reduce patients' serum insulin levels compared with glibenclamide monotherapy. For newly diagnosed T2DM patients, there was no statistical difference in body mass index (BMI), waist circumference and HbA1c between 8 weeks of treatment with glipizide controlled-release tablets combined with acarbose and glipizide controlled-release tablets alone. However, the former could significantly improve patients' HOMA-IR, reduce postprandial blood glucose increment, and effectively reduce blood glucose fluctuations (inter-day blood glucose variability and intra-day blood glucose variability)."
    },
    {
      "paragraph_id": "26",
      "paragraph": "3.5 磺脲类药物联合噻唑烷二酮类药物的疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.5 磺脲类药物联合噻唑烷二酮类药物的疗效如何? ",
          "start_idx": 0,
          "end_idx": 26,
          "entities": [
            {
              "entity_id": "T204",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T205",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 19,
              "entity_en": "Thiazolidinediones"
            }
          ],
          "relations": [],
          "sentence_en": "3.5 What is the efficacy of sulfonylureas combined with thiazolidinediones?"
        }
      ],
      "paragraph_en": "3.5 What is the efficacy of sulfonylureas combined with thiazolidinediones?"
    },
    {
      "paragraph_id": "27",
      "paragraph": "磺脲类药物单药治疗血糖控制不佳时，联合噻唑烷二酮类药物治疗可以进一步改善血糖，减轻胰岛素抵抗。随机、双盲、安慰剂对照研究结果显示，患者使用罗格列酮4mg联合磺脲类药物和罗格列酮8mg联合磺脲类药物治疗24周，HbA1c分别下降1.04%和1.44%，空腹血糖分别下降1.2mmol/L和2.0mmol/L，血中胰岛素水平较基线分别下降23.3pmol/L和30.4pmol/L，但患者体重增加更明显。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物单药治疗血糖控制不佳时，联合噻唑烷二酮类药物治疗可以进一步改善血糖，减轻胰岛素抵抗。随机、双盲、安慰剂对照研究结果显示，患者使用罗格列酮4mg联合磺脲类药物和罗格列酮8mg联合磺脲类药物治疗24周，HbA1c分别下降1.04%和1.44%，空腹血糖分别下降1.2mmol/L和2.0mmol/L，血中胰岛素水平较基线分别下降23.3pmol/L和30.4pmol/L，但患者体重增加更明显。",
          "start_idx": 0,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T206",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T207",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 27,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T208",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T209",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T210",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T211",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 98,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T212",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T213",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 38,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T214",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 104,
              "end_idx": 109,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T215",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 125,
              "end_idx": 129,
              "entity_en": "Fasting blood sugar"
            },
            {
              "entity_id": "T216",
              "entity": "血中胰岛素水平",
              "entity_type": "Test_items",
              "start_idx": 153,
              "end_idx": 160,
              "entity_en": "Blood insulin levels"
            },
            {
              "entity_id": "T217",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T218",
              "entity": "分别下降1.04%和1.44%",
              "entity_type": "Test_Value",
              "start_idx": 109,
              "end_idx": 124,
              "entity_en": "Down 1.04% and 1.44% respectively"
            },
            {
              "entity_id": "T219",
              "entity": "下降1.2mmol/L和2.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 131,
              "end_idx": 152,
              "entity_en": "Decreased by 1.2mmol/L and 2.0mmol/L"
            },
            {
              "entity_id": "T220",
              "entity": "下降23.3pmol/L和30.4pmol/L",
              "entity_type": "Test_Value",
              "start_idx": 165,
              "end_idx": 188,
              "entity_en": "Decreased by 23.3pmol/L and 30.4pmol/L"
            },
            {
              "entity_id": "T221",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "Insulin resistance"
            },
            {
              "entity_id": "T222",
              "entity": "4mg",
              "entity_type": "Amount",
              "start_idx": 73,
              "end_idx": 76,
              "entity_en": "4mg"
            },
            {
              "entity_id": "T223",
              "entity": "8mg",
              "entity_type": "Amount",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "8mg"
            },
            {
              "entity_id": "T224",
              "entity": "24周",
              "entity_type": "Duration",
              "start_idx": 100,
              "end_idx": 103,
              "entity_en": "24 weeks"
            },
            {
              "entity_id": "T225",
              "entity": "体重增加更明显",
              "entity_type": "ADE",
              "start_idx": 192,
              "end_idx": 199,
              "entity_en": "More significant weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R73",
              "head_entity_id": "T222",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R74",
              "head_entity_id": "T224",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R75",
              "head_entity_id": "T225",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R76",
              "head_entity_id": "T224",
              "tail_entity_id": "T209"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R77",
              "head_entity_id": "T225",
              "tail_entity_id": "T209"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R78",
              "head_entity_id": "T223",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R79",
              "head_entity_id": "T224",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R80",
              "head_entity_id": "T225",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R81",
              "head_entity_id": "T224",
              "tail_entity_id": "T211"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R82",
              "head_entity_id": "T225",
              "tail_entity_id": "T211"
            }
          ],
          "sentence_en": "When sulfonylurea monotherapy fails to control blood sugar, combined treatment with thiazolidinediones can further improve blood sugar and reduce insulin resistance. The results of a randomized, double-blind, placebo-controlled study showed that patients treated with rosiglitazone 4 mg combined with sulfonylureas and rosiglitazone 8 mg combined with sulfonylureas for 24 weeks had HbA1c decreases of 1.04% and 1.44%, fasting blood sugar decreases of 1.2 mmol/L and 2.0 mmol/L, respectively, and blood insulin levels decreased by 23.3 pmol/L and 30.4 pmol/L, respectively, compared with baseline, but patients gained more weight."
        }
      ],
      "paragraph_en": "When sulfonylurea monotherapy fails to control blood sugar, combined treatment with thiazolidinediones can further improve blood sugar and reduce insulin resistance. The results of a randomized, double-blind, placebo-controlled study showed that patients treated with rosiglitazone 4 mg combined with sulfonylureas and rosiglitazone 8 mg combined with sulfonylureas for 24 weeks had HbA1c decreases of 1.04% and 1.44%, fasting blood sugar decreases of 1.2 mmol/L and 2.0 mmol/L, respectively, and blood insulin levels decreased by 23.3 pmol/L and 30.4 pmol/L, respectively, compared with baseline, but patients gained more weight."
    },
    {
      "paragraph_id": "28",
      "paragraph": "3.6 磺脲类药物联合二肽基肽酶-4抑制剂的疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.6 磺脲类药物联合二肽基肽酶-4抑制剂的疗效如何? ",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T226",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T227",
              "entity": "二肽基肽酶-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 21,
              "entity_en": "Dipeptidyl peptidase-4 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "3.6 What is the efficacy of sulfonylureas combined with dipeptidyl peptidase-4 inhibitors?"
        }
      ],
      "paragraph_en": "3.6 What is the efficacy of sulfonylureas combined with dipeptidyl peptidase-4 inhibitors?"
    },
    {
      "paragraph_id": "29",
      "paragraph": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂通过降低DPP-4酶的催化活性，抑制胰高血糖素样肽-1(glucagon-like peptide-1，GLP-1)降解，提升GLP-1在血液中的浓度，刺激胰岛素和抑制胰高血糖素分泌，从而达到控制血糖的目的。磺脲类药物单药治疗血糖控制不佳时，联合DPP-4抑制剂可更好地控制血糖。一项为期24周的多中心、随机、双盲、安慰剂对照研究结果显示，格列美脲联合维格列汀50mg/d或100mg/d不但有效降低患者的HbA1c水平，同时改善患者β细胞功能和餐后血糖水平，且对于年龄≥65岁的老年患者同样安全、有效。磺脲类药物联合DPP-4抑制剂会增加低血糖的发生风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂通过降低DPP-4酶的催化活性，抑制胰高血糖素样肽-1(glucagon-like peptide-1，GLP-1)降解，提升GLP-1在血液中的浓度，刺激胰岛素和抑制胰高血糖素分泌，从而达到控制血糖的目的。磺脲类药物单药治疗血糖控制不佳时，联合DPP-4抑制剂可更好地控制血糖。一项为期24周的多中心、随机、双盲、安慰剂对照研究结果显示，格列美脲联合维格列汀50mg/d或100mg/d不但有效降低患者的HbA1c水平，同时改善患者β细胞功能和餐后血糖水平，且对于年龄≥65岁的老年患者同样安全、有效。磺脲类药物联合DPP-4抑制剂会增加低血糖的发生风险。",
          "start_idx": 0,
          "end_idx": 319,
          "entities": [
            {
              "entity_id": "T228",
              "entity": "二肽基肽酶-4(dipeptidyl peptidase-4，DPP-4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 40,
              "entity_en": "Dipeptidyl peptidase-4 (DPP-4) inhibitors"
            },
            {
              "entity_id": "T229",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 149,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T230",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 171,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T231",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 210,
              "end_idx": 214,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T232",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 216,
              "end_idx": 220,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T233",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 138,
              "end_idx": 140,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T234",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T235",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 177,
              "end_idx": 179,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T236",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 243,
              "end_idx": 248,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T237",
              "entity": "餐后血糖水平",
              "entity_type": "Test_items",
              "start_idx": 263,
              "end_idx": 269,
              "entity_en": "Postprandial blood sugar levels"
            },
            {
              "entity_id": "T238",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 292,
              "end_idx": 297,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T239",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 299,
              "end_idx": 307,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T240",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 310,
              "end_idx": 313,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T241",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 155,
              "end_idx": 159,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T242",
              "entity": "50mg/d",
              "entity_type": "Amount",
              "start_idx": 220,
              "end_idx": 226,
              "entity_en": "50 mg/day"
            },
            {
              "entity_id": "T243",
              "entity": "100mg/d",
              "entity_type": "Amount",
              "start_idx": 227,
              "end_idx": 234,
              "entity_en": "100 mg/day"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R83",
              "head_entity_id": "T242",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R84",
              "head_entity_id": "T243",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R85",
              "head_entity_id": "T240",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R86",
              "head_entity_id": "T240",
              "tail_entity_id": "T239"
            }
          ],
          "sentence_en": "Dipeptidyl peptidase-4 (DPP-4) inhibitors inhibit the degradation of glucagon-like peptide-1 (GLP-1) by reducing the catalytic activity of DPP-4 enzyme, thereby increasing the concentration of GLP-1 in the blood, stimulating insulin and inhibiting glucagon secretion, thereby achieving the purpose of controlling blood sugar. When sulfonylurea monotherapy has poor blood sugar control, the combination of DPP-4 inhibitors can better control blood sugar. The results of a 24-week multicenter, randomized, double-blind, placebo-controlled study showed that glimepiride combined with vildagliptin 50 mg/d or 100 mg/d not only effectively reduced the patient's HbA1c level, but also improved the patient's β-cell function and postprandial blood sugar level, and was also safe and effective for elderly patients aged ≥65 years. Sulfonylurea combined with DPP-4 inhibitors increases the risk of hypoglycemia."
        }
      ],
      "paragraph_en": "Dipeptidyl peptidase-4 (DPP-4) inhibitors inhibit the degradation of glucagon-like peptide-1 (GLP-1) by reducing the catalytic activity of DPP-4 enzyme, thereby increasing the concentration of GLP-1 in the blood, stimulating insulin and inhibiting glucagon secretion, thereby achieving the purpose of controlling blood sugar. When sulfonylurea monotherapy has poor blood sugar control, the combination of DPP-4 inhibitors can better control blood sugar. The results of a 24-week multicenter, randomized, double-blind, placebo-controlled study showed that glimepiride combined with vildagliptin 50 mg/d or 100 mg/d not only effectively reduced the patient's HbA1c level, but also improved the patient's β-cell function and postprandial blood sugar level, and was also safe and effective for elderly patients aged ≥65 years. Sulfonylurea combined with DPP-4 inhibitors increases the risk of hypoglycemia."
    },
    {
      "paragraph_id": "30",
      "paragraph": "3.7 磺脲类药物联合SGLT-2抑制剂的疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.7 磺脲类药物联合SGLT-2抑制剂的疗效如何? ",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T244",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T245",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 20,
              "entity_en": "SGLT-2 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "3.7 What is the efficacy of sulfonylureas combined with SGLT-2 inhibitors?"
        }
      ],
      "paragraph_en": "3.7 What is the efficacy of sulfonylureas combined with SGLT-2 inhibitors?"
    },
    {
      "paragraph_id": "31",
      "paragraph": "SGLT-2抑制剂通过抑制近端肾小管钠-葡萄糖重吸收、促进尿糖排泄降低血糖浓度。磺脲类药物联合SGLT-2抑制剂可进一步降低患者血糖，并减轻患者体重，但两者联用应注意低血糖风险。一项为期48周的随机、双盲、对照研究结果显示，格列美脲治疗血糖控制不佳的T2DM患者，联合使用达格列净(dapagliflozin)2.5mg/d、5mg/d、10mg/d后，HbA1c分别进一步下降0.41%、0.56%和0.73%，体重降幅分为1.36kg、1.54kg、2.41kg，低血糖发生率为9.7%~11.3%。一项为期24周随机双盲试验和28周开放标签延长期试验的研究结果显示，与安慰剂比较，鲁格列净(Luseogliflozin)联合磺脲类药物可进一步降低患者HbA1c0.63%，低血糖事件发生率为10.7%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂通过抑制近端肾小管钠-葡萄糖重吸收、促进尿糖排泄降低血糖浓度。磺脲类药物联合SGLT-2抑制剂可进一步降低患者血糖，并减轻患者体重，但两者联用应注意低血糖风险。一项为期48周的随机、双盲、对照研究结果显示，格列美脲治疗血糖控制不佳的T2DM患者，联合使用达格列净(dapagliflozin)2.5mg/d、5mg/d、10mg/d后，HbA1c分别进一步下降0.41%、0.56%和0.73%，体重降幅分为1.36kg、1.54kg、2.41kg，低血糖发生率为9.7%~11.3%。一项为期24周随机双盲试验和28周开放标签延长期试验的研究结果显示，与安慰剂比较，鲁格列净(Luseogliflozin)联合磺脲类药物可进一步降低患者HbA1c0.63%，低血糖事件发生率为10.7%。",
          "start_idx": 0,
          "end_idx": 354,
          "entities": [
            {
              "entity_id": "T246",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T247",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 45,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T248",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 56,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T249",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T250",
              "entity": "达格列净(dapagliflozin)",
              "entity_type": "Drug",
              "start_idx": 136,
              "end_idx": 155,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T251",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 315,
              "end_idx": 320,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T252",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 37,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T253",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T254",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T255",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 177,
              "end_idx": 182,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T256",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 328,
              "end_idx": 333,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T257",
              "entity": "减轻患者体重",
              "entity_type": "ADE",
              "start_idx": 68,
              "end_idx": 74,
              "entity_en": "Reduce patient weight"
            },
            {
              "entity_id": "T258",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T259",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 234,
              "end_idx": 237,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T260",
              "entity": "鲁格列净(Luseogliflozin)",
              "entity_type": "Drug",
              "start_idx": 293,
              "end_idx": 313,
              "entity_en": "Luseogliflozin"
            },
            {
              "entity_id": "T261",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 339,
              "end_idx": 342,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T262",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 125,
              "end_idx": 127,
              "entity_en": "T2"
            },
            {
              "entity_id": "T263",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 125,
              "end_idx": 129,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T264",
              "entity": "2.5mg/d",
              "entity_type": "Amount",
              "start_idx": 155,
              "end_idx": 162,
              "entity_en": "2.5 mg/day"
            },
            {
              "entity_id": "T265",
              "entity": "5mg/d",
              "entity_type": "Amount",
              "start_idx": 163,
              "end_idx": 168,
              "entity_en": "5 mg/day"
            },
            {
              "entity_id": "T266",
              "entity": "10mg/d",
              "entity_type": "Amount",
              "start_idx": 169,
              "end_idx": 175,
              "entity_en": "10 mg/day"
            },
            {
              "entity_id": "T267",
              "entity": "下降0.41%、0.56%和0.73%",
              "entity_type": "Test_Value",
              "start_idx": 187,
              "end_idx": 206,
              "entity_en": "Down 0.41%, 0.56% and 0.73%"
            },
            {
              "entity_id": "T268",
              "entity": "0.63%",
              "entity_type": "Test_Value",
              "start_idx": 333,
              "end_idx": 338,
              "entity_en": "0.63%"
            },
            {
              "entity_id": "T269",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 120,
              "end_idx": 124,
              "entity_en": "Poor control"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R87",
              "head_entity_id": "T257",
              "tail_entity_id": "T247"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R88",
              "head_entity_id": "T258",
              "tail_entity_id": "T247"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R89",
              "head_entity_id": "T257",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R90",
              "head_entity_id": "T258",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R91",
              "head_entity_id": "T259",
              "tail_entity_id": "T249"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R92",
              "head_entity_id": "T249",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R93",
              "head_entity_id": "T264",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R94",
              "head_entity_id": "T265",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R95",
              "head_entity_id": "T266",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R96",
              "head_entity_id": "T259",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R97",
              "head_entity_id": "T250",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R98",
              "head_entity_id": "T261",
              "tail_entity_id": "T251"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R99",
              "head_entity_id": "T254",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R100",
              "head_entity_id": "T261",
              "tail_entity_id": "T260"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R101",
              "head_entity_id": "T262",
              "tail_entity_id": "T263"
            }
          ],
          "sentence_en": "SGLT-2 inhibitors reduce blood glucose concentration by inhibiting proximal tubular sodium-glucose reabsorption and promoting urinary glucose excretion. Sulfonylureas combined with SGLT-2 inhibitors can further reduce blood glucose and body weight in patients, but the risk of hypoglycemia should be noted when the two are used together. The results of a 48-week randomized, double-blind, controlled study showed that after glimepiride was used in combination with dapagliflozin 2.5 mg/d, 5 mg/d, and 10 mg/d in patients with T2DM with poor blood glucose control, HbA1c was further reduced by 0.41%, 0.56%, and 0.73%, respectively, and the weight loss was 1.36 kg, 1.54 kg, and 2.41 kg, respectively, and the incidence of hypoglycemia was 9.7% to 11.3%. The results of a 24-week randomized double-blind trial and a 28-week open-label extension trial showed that compared with placebo, Luseogliflozin combined with sulfonylureas can further reduce patients' HbA1c by 0.63%, and the incidence of hypoglycemia events was 10.7%."
        }
      ],
      "paragraph_en": "SGLT-2 inhibitors reduce blood glucose concentration by inhibiting proximal tubular sodium-glucose reabsorption and promoting urinary glucose excretion. Sulfonylureas combined with SGLT-2 inhibitors can further reduce blood glucose and body weight in patients, but the risk of hypoglycemia should be noted when the two are used together. The results of a 48-week randomized, double-blind, controlled study showed that after glimepiride was used in combination with dapagliflozin 2.5 mg/d, 5 mg/d, and 10 mg/d in patients with T2DM with poor blood glucose control, HbA1c was further reduced by 0.41%, 0.56%, and 0.73%, respectively, and the weight loss was 1.36 kg, 1.54 kg, and 2.41 kg, respectively, and the incidence of hypoglycemia was 9.7% to 11.3%. The results of a 24-week randomized double-blind trial and a 28-week open-label extension trial showed that compared with placebo, Luseogliflozin combined with sulfonylureas can further reduce patients' HbA1c by 0.63%, and the incidence of hypoglycemia events was 10.7%."
    },
    {
      "paragraph_id": "32",
      "paragraph": "3.8 磺脲类药物联合GLP-1受体激动剂的疗效如何?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.8 磺脲类药物联合GLP-1受体激动剂的疗效如何?",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T270",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T271",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 21,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [],
          "sentence_en": "3.8 What is the efficacy of sulfonylureas combined with GLP-1 receptor agonists?"
        }
      ],
      "paragraph_en": "3.8 What is the efficacy of sulfonylureas combined with GLP-1 receptor agonists?"
    },
    {
      "paragraph_id": "33",
      "paragraph": "GLP-1受体激动剂以葡萄糖浓度依赖的方式促进β细胞分泌胰岛素、降低α细胞分泌胰血高糖素，磺脲类药物联合GLP-1受体激动剂可使HbA1c水平显著降低，且安全耐受性良好。一项为期26周的随机、双盲、对照研究结果显示，无论之前患者接受何种治疗，格列美脲联合利拉鲁肽治疗均可快速降低HbA1c达1.1%，显著优于格列美脲单药治疗或格列美脲联合罗格列酮治疗。格列美脲联合利拉鲁肽1.8mg/d治疗组患者体重降低，<10%的患者发生轻度低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP-1受体激动剂以葡萄糖浓度依赖的方式促进β细胞分泌胰岛素、降低α细胞分泌胰血高糖素，磺脲类药物联合GLP-1受体激动剂可使HbA1c水平显著降低，且安全耐受性良好。一项为期26周的随机、双盲、对照研究结果显示，无论之前患者接受何种治疗，格列美脲联合利拉鲁肽治疗均可快速降低HbA1c达1.1%，显著优于格列美脲单药治疗或格列美脲联合罗格列酮治疗。格列美脲联合利拉鲁肽1.8mg/d治疗组患者体重降低，<10%的患者发生轻度低血糖。",
          "start_idx": 0,
          "end_idx": 218,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 10,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T273",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 50,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T274",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 62,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T275",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T276",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T277",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 154,
              "end_idx": 158,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T278",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T279",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 173,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T280",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 176,
              "end_idx": 180,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T281",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 186,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T282",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 69,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T283",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 139,
              "end_idx": 144,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T284",
              "entity": "1.1%",
              "entity_type": "Test_Value",
              "start_idx": 145,
              "end_idx": 149,
              "entity_en": "1.1%"
            },
            {
              "entity_id": "T285",
              "entity": "显著降低",
              "entity_type": "Test_Value",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "Significantly reduce"
            },
            {
              "entity_id": "T286",
              "entity": "1.8mg/d",
              "entity_type": "Amount",
              "start_idx": 186,
              "end_idx": 193,
              "entity_en": "1.8 mg/day"
            },
            {
              "entity_id": "T287",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 214,
              "end_idx": 217,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T288",
              "entity": "体重降低",
              "entity_type": "ADE",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "Weight loss"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R102",
              "head_entity_id": "T288",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R103",
              "head_entity_id": "T287",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R104",
              "head_entity_id": "T286",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R105",
              "head_entity_id": "T288",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R106",
              "head_entity_id": "T287",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R107",
              "head_entity_id": "T286",
              "tail_entity_id": "T281"
            }
          ],
          "sentence_en": "GLP-1 receptor agonists promote insulin secretion from β cells and reduce glucagon secretion from α cells in a glucose concentration-dependent manner. Sulfonylureas combined with GLP-1 receptor agonists can significantly reduce HbA1c levels with good safety and tolerance. The results of a 26-week randomized, double-blind, controlled study showed that regardless of the previous treatment received by the patient, glimepiride combined with liraglutide treatment can quickly reduce HbA1c by 1.1%, which is significantly better than glimepiride monotherapy or glimepiride combined with rosiglitazone treatment. Patients in the glimepiride combined with liraglutide 1.8 mg/d treatment group lost weight, and <10% of patients experienced mild hypoglycemia."
        }
      ],
      "paragraph_en": "GLP-1 receptor agonists promote insulin secretion from β cells and reduce glucagon secretion from α cells in a glucose concentration-dependent manner. Sulfonylureas combined with GLP-1 receptor agonists can significantly reduce HbA1c levels with good safety and tolerance. The results of a 26-week randomized, double-blind, controlled study showed that regardless of the previous treatment received by the patient, glimepiride combined with liraglutide treatment can quickly reduce HbA1c by 1.1%, which is significantly better than glimepiride monotherapy or glimepiride combined with rosiglitazone treatment. Patients in the glimepiride combined with liraglutide 1.8 mg/d treatment group lost weight, and <10% of patients experienced mild hypoglycemia."
    },
    {
      "paragraph_id": "34",
      "paragraph": "3.9 磺脲类药物联合胰岛素的临床疗效如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.9 磺脲类药物联合胰岛素的临床疗效如何? ",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T289",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T290",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "3.9 What is the clinical efficacy of sulfonylureas combined with insulin?"
        }
      ],
      "paragraph_en": "3.9 What is the clinical efficacy of sulfonylureas combined with insulin?"
    },
    {
      "paragraph_id": "35",
      "paragraph": "一般情况下，不推荐磺脲类药物联合胰岛素治疗T2DM，但胰岛细胞尚有部分分泌功能的T2DM患者可考虑使用磺脲类药物联合基础胰岛素治疗。当单一或联合口服降糖药无法满意控制血糖时，口服降糖药物(包括磺脲类药物)联合基础胰岛素可以作为一种胰岛素起始的治疗方案。在亚洲多个国",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一般情况下，不推荐磺脲类药物联合胰岛素治疗T2DM，但胰岛细胞尚有部分分泌功能的T2DM患者可考虑使用磺脲类药物联合基础胰岛素治疗。当单一或联合口服降糖药无法满意控制血糖时，口服降糖药物(包括磺脲类药物)联合基础胰岛素可以作为一种胰岛素起始的治疗方案。",
          "start_idx": 0,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T291",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T292",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T293",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 56,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T294",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T295",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 101,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T296",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 109,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T297",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 87,
              "end_idx": 89,
              "entity_en": "oral"
            },
            {
              "entity_id": "T298",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "oral"
            },
            {
              "entity_id": "T299",
              "entity": "胰岛",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "Pancreatic Islets"
            },
            {
              "entity_id": "T300",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "T2"
            },
            {
              "entity_id": "T301",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T302",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "T2"
            },
            {
              "entity_id": "T303",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T304",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 85,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R108",
              "head_entity_id": "T293",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R109",
              "head_entity_id": "T294",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R110",
              "head_entity_id": "T297",
              "tail_entity_id": "T295"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R111",
              "head_entity_id": "T297",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R112",
              "head_entity_id": "T300",
              "tail_entity_id": "T301"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R113",
              "head_entity_id": "T302",
              "tail_entity_id": "T303"
            }
          ],
          "sentence_en": "Generally, sulfonylureas combined with insulin are not recommended for the treatment of T2DM, but patients with T2DM who still have some secretory function of pancreatic islet cells can consider using sulfonylureas combined with basal insulin. When single or combined oral hypoglycemic drugs cannot satisfactorily control blood sugar, oral hypoglycemic drugs (including sulfonylureas) combined with basal insulin can be used as an insulin-initiated treatment option."
        },
        {
          "sentence_id": "1",
          "sentence": "在亚洲多个国",
          "start_idx": 126,
          "end_idx": 132,
          "entities": [],
          "relations": [],
          "sentence_en": "In many countries in Asia"
        }
      ],
      "paragraph_en": "Generally, sulfonylureas combined with insulin are not recommended for the treatment of T2DM, but patients with T2DM who still have some secretory function of pancreatic islet cells may consider using sulfonylureas combined with basal insulin. When single or combined oral hypoglycemic drugs cannot satisfactorily control blood sugar, oral hypoglycemic drugs (including sulfonylureas) combined with basal insulin can be used as an insulin-initiated treatment option."
    },
    {
      "paragraph_id": "36",
      "paragraph": "家进行的一项443例T2DM患者参加的多中心、随机、对照研究显示，对于既往未接受胰岛素治疗的T2DM患者，格列美脲联合甘精胰岛素可进一步降低HbA1c达0.99%，HbA1c达标率为38.1%，空腹血糖降低幅度为5.89mmol/L，与格列美脲联合重组人胰岛素(NPH)组无差异，平均日间血糖降低幅度优于NPH组(-5.22mmol/L vs -4.44mmol/L)，总体低血糖发生682/220(次数/例数)，症状性低血糖为515/220(次数/例数)，严重低血糖为5/220(次数/例数)。接受磺脲类药物联合基础胰岛素治疗的患者应特别注意饮食和运动量，以及体重增加和低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "家进行的一项443例T2DM患者参加的多中心、随机、对照研究显示，对于既往未接受胰岛素治疗的T2DM患者，格列美脲联合甘精胰岛素可进一步降低HbA1c达0.99%，HbA1c达标率为38.1%，空腹血糖降低幅度为5.89mmol/L，与格列美脲联合重组人胰岛素(NPH)组无差异，平均日间血糖降低幅度优于NPH组(-5.22mmol/L vs -4.44mmol/L)，总体低血糖发生682/220(次数/例数)，症状性低血糖为515/220(次数/例数)，严重低血糖为5/220(次数/例数)。接受磺脲类药物联合基础胰岛素治疗的患者应特别注意饮食和运动量，以及体重增加和低血糖。",
          "start_idx": 0,
          "end_idx": 290,
          "entities": [
            {
              "entity_id": "T305",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T306",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T307",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 64,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T308",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 122,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T309",
              "entity": "重组人胰岛素(NPH)",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 135,
              "entity_en": "Recombinant human insulin (NPH)"
            },
            {
              "entity_id": "T310",
              "entity": "NPH",
              "entity_type": "Drug",
              "start_idx": 152,
              "end_idx": 155,
              "entity_en": "NPH"
            },
            {
              "entity_id": "T311",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 250,
              "end_idx": 255,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T312",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 257,
              "end_idx": 262,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T313",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "T2"
            },
            {
              "entity_id": "T314",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T315",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 46,
              "end_idx": 48,
              "entity_en": "T2"
            },
            {
              "entity_id": "T316",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T317",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 70,
              "end_idx": 75,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T318",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 87,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T319",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 97,
              "end_idx": 101,
              "entity_en": "Fasting blood sugar"
            },
            {
              "entity_id": "T320",
              "entity": "平均日间血糖降低幅度",
              "entity_type": "Test_items",
              "start_idx": 140,
              "end_idx": 150,
              "entity_en": "Average daily blood sugar reduction"
            },
            {
              "entity_id": "T321",
              "entity": "0.99%",
              "entity_type": "Test_Value",
              "start_idx": 76,
              "end_idx": 81,
              "entity_en": "0.99%"
            },
            {
              "entity_id": "T322",
              "entity": "38.1%",
              "entity_type": "Test_Value",
              "start_idx": 91,
              "end_idx": 96,
              "entity_en": "38.1%"
            },
            {
              "entity_id": "T323",
              "entity": "5.89mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 106,
              "end_idx": 116,
              "entity_en": "5.89mmol/L"
            },
            {
              "entity_id": "T324",
              "entity": "-5.22mmol/L vs -4.44mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 157,
              "end_idx": 183,
              "entity_en": "-5.22mmol/L vs -4.44mmol/L"
            },
            {
              "entity_id": "T325",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 187,
              "end_idx": 190,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T326",
              "entity": "症状性低血糖",
              "entity_type": "ADE",
              "start_idx": 207,
              "end_idx": 213,
              "entity_en": "Symptomatic hypoglycemia"
            },
            {
              "entity_id": "T327",
              "entity": "严重低血糖",
              "entity_type": "ADE",
              "start_idx": 229,
              "end_idx": 234,
              "entity_en": "Severe hypoglycemia"
            },
            {
              "entity_id": "T328",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 281,
              "end_idx": 285,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T329",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 286,
              "end_idx": 289,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R114",
              "head_entity_id": "T306",
              "tail_entity_id": "T316"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R115",
              "head_entity_id": "T325",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R116",
              "head_entity_id": "T326",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R117",
              "head_entity_id": "T327",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R118",
              "head_entity_id": "T307",
              "tail_entity_id": "T316"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R119",
              "head_entity_id": "T325",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R120",
              "head_entity_id": "T326",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R121",
              "head_entity_id": "T327",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R122",
              "head_entity_id": "T328",
              "tail_entity_id": "T311"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R123",
              "head_entity_id": "T329",
              "tail_entity_id": "T311"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R124",
              "head_entity_id": "T328",
              "tail_entity_id": "T312"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R125",
              "head_entity_id": "T329",
              "tail_entity_id": "T312"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R126",
              "head_entity_id": "T313",
              "tail_entity_id": "T314"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R127",
              "head_entity_id": "T315",
              "tail_entity_id": "T316"
            }
          ],
          "sentence_en": "A multicenter, randomized, controlled study conducted by the National Medical Research Council of China with 443 patients with T2DM showed that for patients with T2DM who had not received insulin treatment before, glimepiride combined with insulin glargine could further reduce HbA1c by 0.99%, and the HbA1c target rate was 38.1%. The reduction in fasting blood glucose was 5.89mmol/L, which was no different from the glimepiride combined with recombinant human insulin (NPH) group. The average daytime blood glucose reduction was better than the NPH group (-5.22mmol/L vs -4.44mmol/L). The overall incidence of hypoglycemia was 682/220 (times/cases), symptomatic hypoglycemia was 515/220 (times/cases), and severe hypoglycemia was 5/220 (times/cases). Patients receiving sulfonylureas combined with basal insulin should pay special attention to diet and exercise, as well as weight gain and hypoglycemia."
        }
      ],
      "paragraph_en": "A multicenter, randomized, controlled study conducted by the National Medical Research Council of China with 443 patients with T2DM showed that for patients with T2DM who had not received insulin treatment before, glimepiride combined with insulin glargine could further reduce HbA1c by 0.99%, and the HbA1c target rate was 38.1%. The reduction in fasting blood glucose was 5.89mmol/L, which was no different from the glimepiride combined with recombinant human insulin (NPH) group. The average daytime blood glucose reduction was better than the NPH group (-5.22mmol/L vs -4.44mmol/L). The overall incidence of hypoglycemia was 682/220 (times/cases), symptomatic hypoglycemia was 515/220 (times/cases), and severe hypoglycemia was 5/220 (times/cases). Patients receiving sulfonylureas combined with basal insulin should pay special attention to diet and exercise, as well as weight gain and hypoglycemia."
    },
    {
      "paragraph_id": "37",
      "paragraph": "4 特殊人群用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4 特殊人群用药",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": [],
          "sentence_en": "4 Use in special populations"
        }
      ],
      "paragraph_en": "4 Use in special populations"
    },
    {
      "paragraph_id": "38",
      "paragraph": "4.1 肝功能不全的T2DM患者是否可以使用磺脲类药物? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.1 肝功能不全的T2DM患者是否可以使用磺脲类药物? ",
          "start_idx": 0,
          "end_idx": 29,
          "entities": [
            {
              "entity_id": "T330",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T331",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5,
              "entity_en": "liver"
            },
            {
              "entity_id": "T332",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "T2"
            },
            {
              "entity_id": "T333",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T334",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R128",
              "head_entity_id": "T331",
              "tail_entity_id": "T330"
            }
          ],
          "sentence_en": "4.1 Can sulfonylureas be used in patients with T2DM and hepatic impairment?"
        }
      ],
      "paragraph_en": "4.1 Can sulfonylureas be used in patients with T2DM and hepatic impairment?"
    },
    {
      "paragraph_id": "39",
      "paragraph": "目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(alanine transaminase，ALT)>3倍参考值上限可作为肝损害的敏感而特异的指标，若ALT>8~10倍参考值上限或者ALT>3倍参考值上限且血清总胆红素(total bilirubin，TBIL)>2倍参考值上限则是预测重度肝损害的特异指标，表明肝脏实质细胞受到损害，此时应禁用磺脲类药物。在临床使用中，伴有肝性脑病、腹水或凝血障碍的失代偿肝硬化患者应禁用该类药物以防发生低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前所有磺脲类药物说明书均将重度肝功能不全列为禁忌证。丙氨酸氨基转移酶(alanine transaminase，ALT)>3倍参考值上限可作为肝损害的敏感而特异的指标，若ALT>8~10倍参考值上限或者ALT>3倍参考值上限且血清总胆红素(total bilirubin，TBIL)>2倍参考值上限则是预测重度肝损害的特异指标，表明肝脏实质细胞受到损害，此时应禁用磺脲类药物。在临床使用中，伴有肝性脑病、腹水或凝血障碍的失代偿肝硬化患者应禁用该类药物以防发生低血糖。",
          "start_idx": 0,
          "end_idx": 234,
          "entities": [
            {
              "entity_id": "T335",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T336",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T337",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 21,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T338",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 16,
              "end_idx": 17,
              "entity_en": "liver"
            },
            {
              "entity_id": "T339",
              "entity": "丙氨酸氨基转移酶(alanine transaminase，ALT)",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 61,
              "entity_en": "Alanine transaminase (ALT)"
            },
            {
              "entity_id": "T340",
              "entity": ">3",
              "entity_type": "Test_Value",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": ">3"
            },
            {
              "entity_id": "T341",
              "entity": "肝损害",
              "entity_type": "ADE",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "Liver damage"
            },
            {
              "entity_id": "T342",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "ALT"
            },
            {
              "entity_id": "T343",
              "entity": ">8~10",
              "entity_type": "Test_Value",
              "start_idx": 89,
              "end_idx": 94,
              "entity_en": ">8~10"
            },
            {
              "entity_id": "T344",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 102,
              "end_idx": 105,
              "entity_en": "ALT"
            },
            {
              "entity_id": "T345",
              "entity": ">3",
              "entity_type": "Test_Value",
              "start_idx": 105,
              "end_idx": 107,
              "entity_en": ">3"
            },
            {
              "entity_id": "T346",
              "entity": "血清总胆红素(total bilirubin，TBIL)",
              "entity_type": "Test_items",
              "start_idx": 114,
              "end_idx": 142,
              "entity_en": "Serum total bilirubin (TBIL)"
            },
            {
              "entity_id": "T347",
              "entity": ">2",
              "entity_type": "Test_Value",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": ">2"
            },
            {
              "entity_id": "T348",
              "entity": "重度肝损害",
              "entity_type": "ADE",
              "start_idx": 154,
              "end_idx": 159,
              "entity_en": "Severe liver damage"
            },
            {
              "entity_id": "T349",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 183,
              "end_idx": 188,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T350",
              "entity": "肝性脑病",
              "entity_type": "Disease",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "Hepatic encephalopathy"
            },
            {
              "entity_id": "T351",
              "entity": "腹水",
              "entity_type": "Disease",
              "start_idx": 203,
              "end_idx": 205,
              "entity_en": "ascites"
            },
            {
              "entity_id": "T352",
              "entity": "失代偿肝硬化",
              "entity_type": "Disease",
              "start_idx": 211,
              "end_idx": 217,
              "entity_en": "Decompensated cirrhosis"
            },
            {
              "entity_id": "T353",
              "entity": "凝血障碍",
              "entity_type": "Disease",
              "start_idx": 206,
              "end_idx": 210,
              "entity_en": "Coagulation disorders"
            },
            {
              "entity_id": "T354",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 230,
              "end_idx": 233,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T355",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 198,
              "end_idx": 199,
              "entity_en": "liver"
            },
            {
              "entity_id": "T356",
              "entity": "脑",
              "entity_type": "Anatomy",
              "start_idx": 200,
              "end_idx": 201,
              "entity_en": "brain"
            },
            {
              "entity_id": "T357",
              "entity": "腹",
              "entity_type": "Anatomy",
              "start_idx": 203,
              "end_idx": 204,
              "entity_en": "belly"
            },
            {
              "entity_id": "T358",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 214,
              "end_idx": 215,
              "entity_en": "liver"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R129",
              "head_entity_id": "T341",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R130",
              "head_entity_id": "T354",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R131",
              "head_entity_id": "T348",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R132",
              "head_entity_id": "T338",
              "tail_entity_id": "T337"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R133",
              "head_entity_id": "T355",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R134",
              "head_entity_id": "T356",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R135",
              "head_entity_id": "T357",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R136",
              "head_entity_id": "T358",
              "tail_entity_id": "T352"
            }
          ],
          "sentence_en": "Currently, all sulfonylurea drug instructions list severe liver dysfunction as a contraindication. Alanine transaminase (ALT) > 3 times the upper limit of the reference value can be used as a sensitive and specific indicator of liver damage. If ALT > 8 to 10 times the upper limit of the reference value or ALT > 3 times the upper limit of the reference value and serum total bilirubin (TBIL) > 2 times the upper limit of the reference value, it is a specific indicator for predicting severe liver damage, indicating that the liver parenchymal cells are damaged, and sulfonylurea drugs should be banned at this time. In clinical use, patients with decompensated cirrhosis accompanied by hepatic encephalopathy, ascites or coagulation disorders should not use this type of drug to prevent hypoglycemia."
        }
      ],
      "paragraph_en": "Currently, all sulfonylurea drug instructions list severe liver dysfunction as a contraindication. Alanine transaminase (ALT) > 3 times the upper limit of the reference value can be used as a sensitive and specific indicator of liver damage. If ALT > 8 to 10 times the upper limit of the reference value or ALT > 3 times the upper limit of the reference value and serum total bilirubin (TBIL) > 2 times the upper limit of the reference value, it is a specific indicator for predicting severe liver damage, indicating that the liver parenchymal cells are damaged, and sulfonylurea drugs should be banned at this time. In clinical use, patients with decompensated cirrhosis accompanied by hepatic encephalopathy, ascites or coagulation disorders should not use this type of drug to prevent hypoglycemia."
    },
    {
      "paragraph_id": "40",
      "paragraph": "4.2 肾功能不全的T2DM患者是否可以使用磺脲类药物? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.2 肾功能不全的T2DM患者是否可以使用磺脲类药物? ",
          "start_idx": 0,
          "end_idx": 29,
          "entities": [
            {
              "entity_id": "T359",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T360",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T361",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "T2"
            },
            {
              "entity_id": "T362",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T363",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R137",
              "head_entity_id": "T360",
              "tail_entity_id": "T359"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R138",
              "head_entity_id": "T361",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R139",
              "head_entity_id": "T363",
              "tail_entity_id": "T362"
            }
          ],
          "sentence_en": "4.2 Can sulfonylureas be used in patients with T2DM and renal insufficiency?"
        }
      ],
      "paragraph_en": "4.2 Can sulfonylureas be used in patients with T2DM and renal insufficiency?"
    },
    {
      "paragraph_id": "41",
      "paragraph": "格列本脲本身及其代谢产物均具有降糖活性，肾功能不全的T2DM患者使用格列本脲容易发生严重的低血糖事件；格列美脲的代谢产物在GFR降低的患者中没有额外蓄积风险；其他常用的磺脲类药物如格列喹酮、格列齐特及格列吡嗪，代谢产物均为非活性物质，尤其是格列喹酮，其代谢产物只有5%经肾脏排泄，受肾功能的影响很小，其可用于轻、中度肾功能不全的糖尿病患者。ADVANCE研究发现，格列齐特缓释片具有肾脏保护作用，可降低患者蛋白尿和肾脏事件风险。磺脲类药物在T2DM合并肾功能不全患者中的使用推荐见表3。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列本脲本身及其代谢产物均具有降糖活性，肾功能不全的T2DM患者使用格列本脲容易发生严重的低血糖事件；格列美脲的代谢产物在GFR降低的患者中没有额外蓄积风险；其他常用的磺脲类药物如格列喹酮、格列齐特及格列吡嗪，代谢产物均为非活性物质，尤其是格列喹酮，其代谢产物只有5%经肾脏排泄，受肾功能的影响很小，其可用于轻、中度肾功能不全的糖尿病患者。ADVANCE研究发现，格列齐特缓释片具有肾脏保护作用，可降低患者蛋白尿和肾脏事件风险。",
          "start_idx": 0,
          "end_idx": 214,
          "entities": [
            {
              "entity_id": "T364",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T365",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T366",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T367",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 89,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T368",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 94,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T369",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T370",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T371",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 124,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T372",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 189,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T374",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T375",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 21,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T376",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "T2"
            },
            {
              "entity_id": "T377",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T378",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 45,
              "end_idx": 48,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T379",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T380",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 158,
              "end_idx": 159,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T381",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 164,
              "end_idx": 167,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T382",
              "entity": "蛋白尿",
              "entity_type": "ADE",
              "start_idx": 203,
              "end_idx": 206,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T383",
              "entity": "肾脏事件",
              "entity_type": "ADE",
              "start_idx": 207,
              "end_idx": 211,
              "entity_en": "Renal events"
            },
            {
              "entity_id": "T388",
              "entity": "轻、中度",
              "entity_type": "Level",
              "start_idx": 154,
              "end_idx": 158,
              "entity_en": "Mild to moderate"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R140",
              "head_entity_id": "T365",
              "tail_entity_id": "T377"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R141",
              "head_entity_id": "T371",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R142",
              "head_entity_id": "T382",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R143",
              "head_entity_id": "T383",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R145",
              "head_entity_id": "T375",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R146",
              "head_entity_id": "T376",
              "tail_entity_id": "T377"
            }
          ],
          "sentence_en": "Glyburide and its metabolites have hypoglycemic activity. Patients with T2DM and renal insufficiency are prone to severe hypoglycemia when using glibenclamide. The metabolites of glimepiride have no additional accumulation risk in patients with reduced GFR. The metabolites of other commonly used sulfonylurea drugs such as gliclazide, gliclazide and glipizide are all inactive substances, especially gliclazide, whose metabolites are only 5% excreted by the kidneys and are little affected by renal function. It can be used in diabetic patients with mild to moderate renal insufficiency. The ADVANCE study found that gliclazide extended-release tablets have a renal protective effect and can reduce the risk of proteinuria and renal events in patients."
        },
        {
          "sentence_id": "1",
          "sentence": "磺脲类药物在T2DM合并肾功能不全患者中的使用推荐见表3。",
          "start_idx": 214,
          "end_idx": 243,
          "entities": [
            {
              "entity_id": "T373",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T384",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "T2"
            },
            {
              "entity_id": "T385",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T386",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T387",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T373",
              "tail_entity_id": "T385"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R147",
              "head_entity_id": "T384",
              "tail_entity_id": "T385"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R148",
              "head_entity_id": "T387",
              "tail_entity_id": "T386"
            }
          ],
          "sentence_en": "The recommended use of sulfonylureas in patients with T2DM and renal insufficiency is shown in Table 3."
        }
      ],
      "paragraph_en": "Glyburide and its metabolites have hypoglycemic activity. Patients with T2DM and renal insufficiency are prone to severe hypoglycemia when using glibenclamide. The metabolites of glimepiride have no additional accumulation risk in patients with reduced GFR. The metabolites of other commonly used sulfonylurea drugs such as gliclazide, gliclazide and glipizide are all inactive substances, especially gliclazide, whose metabolites are only 5% excreted by the kidneys and are little affected by renal function. It can be used in diabetic patients with mild to moderate renal insufficiency. The ADVANCE study found that gliclazide sustained-release tablets have a renal protective effect and can reduce the risk of proteinuria and renal events in patients. The recommended use of sulfonylurea drugs in patients with T2DM and renal insufficiency is shown in Table 3."
    },
    {
      "paragraph_id": "42",
      "paragraph": "4.3 老年患者使用磺脲类药物有哪些注意事项? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.3 老年患者使用磺脲类药物有哪些注意事项? ",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T389",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "4.3 What precautions should be taken when elderly patients use sulfonylureas?"
        }
      ],
      "paragraph_en": "4.3 What precautions should be taken when elderly patients use sulfonylureas?"
    },
    {
      "paragraph_id": "43",
      "paragraph": "针对老年糖尿病患者，实施个体化药物治疗方案控制血糖并避免或最小化药物相关的不良反应是必要的。老年糖尿病患者对低血糖耐受性差，易出现无症状性低血糖和严重低血糖，需要特别关注。因此，在选择降糖药物时，老年患者应着重考虑药物的低血糖风险。若患者既往有严重低血糖史、预期生存期较短、或合并其他严重疾病，如果需要联合磺脲类药物治疗，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖的发生风险降至最小。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "针对老年糖尿病患者，实施个体化药物治疗方案控制血糖并避免或最小化药物相关的不良反应是必要的。老年糖尿病患者对低血糖耐受性差，易出现无症状性低血糖和严重低血糖，需要特别关注。因此，在选择降糖药物时，老年患者应着重考虑药物的低血糖风险。若患者既往有严重低血糖史、预期生存期较短、或合并其他严重疾病，如果需要联合磺脲类药物治疗，宜选择降糖作用较温和、作用时间较短、低血糖风险小的磺脲类药物，避免使用格列本脲。无论选择何种磺脲类药物，都应从最小剂量开始，严密监测血糖变化，根据血糖逐步调整至合适剂量，将低血糖的发生风险降至最小。",
          "start_idx": 0,
          "end_idx": 260,
          "entities": [
            {
              "entity_id": "T390",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T391",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T392",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T393",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T394",
              "entity": "无症状性低血糖",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 72,
              "entity_en": "Asymptomatic hypoglycemia"
            },
            {
              "entity_id": "T395",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 110,
              "end_idx": 113,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T396",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 124,
              "end_idx": 127,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T397",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 122,
              "end_idx": 124,
              "entity_en": "serious"
            },
            {
              "entity_id": "T398",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 153,
              "end_idx": 158,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T399",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 179,
              "end_idx": 182,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T400",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 186,
              "end_idx": 191,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T401",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 196,
              "end_idx": 200,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T402",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 212,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T403",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 227,
              "end_idx": 229,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T404",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 234,
              "end_idx": 236,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T405",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 247,
              "end_idx": 250,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T406",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 78,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T407",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 73,
              "end_idx": 75,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R149",
              "head_entity_id": "T391",
              "tail_entity_id": "T390"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R150",
              "head_entity_id": "T399",
              "tail_entity_id": "T400"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R151",
              "head_entity_id": "T399",
              "tail_entity_id": "T401"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R152",
              "head_entity_id": "T405",
              "tail_entity_id": "T402"
            }
          ],
          "sentence_en": "For elderly patients with diabetes, it is necessary to implement individualized drug treatment plans to control blood sugar and avoid or minimize drug-related adverse reactions. Elderly patients with diabetes have poor tolerance to hypoglycemia and are prone to asymptomatic hypoglycemia and severe hypoglycemia, which requires special attention. Therefore, when choosing hypoglycemic drugs, elderly patients should focus on the hypoglycemia risk of the drug. If the patient has a history of severe hypoglycemia, a short expected life span, or other serious diseases, if combined treatment with sulfonylureas is required, it is advisable to choose sulfonylureas with milder hypoglycemic effects, shorter duration of action, and lower risk of hypoglycemia, and avoid the use of glibenclamide. Regardless of the sulfonylurea drug selected, it should be started from the minimum dose, blood sugar changes should be closely monitored, and the dose should be gradually adjusted to the appropriate dose according to blood sugar to minimize the risk of hypoglycemia."
        }
      ],
      "paragraph_en": "For elderly patients with diabetes, it is necessary to implement individualized drug treatment plans to control blood sugar and avoid or minimize drug-related adverse reactions. Elderly patients with diabetes have poor tolerance to hypoglycemia and are prone to asymptomatic hypoglycemia and severe hypoglycemia, which requires special attention. Therefore, when choosing hypoglycemic drugs, elderly patients should focus on the hypoglycemia risk of the drug. If the patient has a history of severe hypoglycemia, a short expected life span, or other serious diseases, if combined treatment with sulfonylureas is required, it is advisable to choose sulfonylureas with milder hypoglycemic effects, shorter duration of action, and lower risk of hypoglycemia, and avoid the use of glibenclamide. Regardless of the sulfonylurea drug selected, it should be started from the minimum dose, blood sugar changes should be closely monitored, and the dose should be gradually adjusted to the appropriate dose according to blood sugar to minimize the risk of hypoglycemia."
    },
    {
      "paragraph_id": "44",
      "paragraph": "4.4 磺脲类药物可否用于T2DM之外的糖尿病患者? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.4 磺脲类药物可否用于T2DM之外的糖尿病患者? ",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T408",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T409",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "T2"
            },
            {
              "entity_id": "T410",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T411",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R153",
              "head_entity_id": "T408",
              "tail_entity_id": "T411"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R154",
              "head_entity_id": "T409",
              "tail_entity_id": "T410"
            }
          ],
          "sentence_en": "4.4 Can sulfonylureas be used in patients with diabetes other than T2DM?"
        }
      ],
      "paragraph_en": "4.4 Can sulfonylureas be used in patients with diabetes other than T2DM?"
    },
    {
      "paragraph_id": "45",
      "paragraph": "目前为止，所有磺脲类药物均尚未被中国食品药品监督管理局(China Food and Drug Administration，CFDA)批准用于治疗妊娠期糖尿病、儿童和青少年T2DM以及1型糖尿病患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前为止，所有磺脲类药物均尚未被中国食品药品监督管理局(China Food and Drug Administration，CFDA)批准用于治疗妊娠期糖尿病、儿童和青少年T2DM以及1型糖尿病患者。",
          "start_idx": 0,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T412",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T413",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 87,
              "end_idx": 89,
              "entity_en": "T2"
            },
            {
              "entity_id": "T414",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 91,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T415",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 93,
              "end_idx": 95,
              "entity_en": "Type 1"
            },
            {
              "entity_id": "T416",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 93,
              "end_idx": 98,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T417",
              "entity": "妊娠期",
              "entity_type": "Class",
              "start_idx": 74,
              "end_idx": 77,
              "entity_en": "Pregnancy"
            },
            {
              "entity_id": "T418",
              "entity": "妊娠期糖尿病",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 80,
              "entity_en": "Gestational diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R155",
              "head_entity_id": "T413",
              "tail_entity_id": "T414"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R156",
              "head_entity_id": "T415",
              "tail_entity_id": "T416"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R157",
              "head_entity_id": "T417",
              "tail_entity_id": "T418"
            }
          ],
          "sentence_en": "So far, all sulfonylurea drugs have not been approved by the China Food and Drug Administration (CFDA) for the treatment of gestational diabetes, T2DM in children and adolescents, and type 1 diabetes patients."
        }
      ],
      "paragraph_en": "So far, all sulfonylurea drugs have not been approved by the China Food and Drug Administration (CFDA) for the treatment of gestational diabetes, T2DM in children and adolescents, and type 1 diabetes patients."
    },
    {
      "paragraph_id": "46",
      "paragraph": "5 安全性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5 安全性",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "5 Security"
        }
      ],
      "paragraph_en": "5 Security"
    },
    {
      "paragraph_id": "47",
      "paragraph": "5.1 磺脲类药物有哪些常见不良反应? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.1 磺脲类药物有哪些常见不良反应? ",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T419",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "5.1 What are the common adverse reactions of sulfonylurea drugs?"
        }
      ],
      "paragraph_en": "5.1 What are the common adverse reactions of sulfonylurea drugs?"
    },
    {
      "paragraph_id": "48",
      "paragraph": "磺脲类药物治疗常见的不良反应有以下几种：①低血糖：临床上起始磺脲类药物剂量过大，或在肝、肾功能不全患者中的不恰当使用可导致低血糖；单药治疗或与其他降糖药物联合治疗均可能出现低血糖。②体重增加。③磺脲类药物与磺胺类药物可发生交叉过敏反应，有磺胺类药物过敏史者应禁用磺脲类药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物治疗常见的不良反应有以下几种：①低血糖：临床上起始磺脲类药物剂量过大，或在肝、肾功能不全患者中的不恰当使用可导致低血糖；单药治疗或与其他降糖药物联合治疗均可能出现低血糖。②体重增加。③磺脲类药物与磺胺类药物可发生交叉过敏反应，有磺胺类药物过敏史者应禁用磺脲类药物。",
          "start_idx": 0,
          "end_idx": 137,
          "entities": [
            {
              "entity_id": "T420",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T421",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 21,
              "end_idx": 24,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T422",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T423",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T424",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 91,
              "end_idx": 95,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T425",
              "entity": "交叉过敏反应",
              "entity_type": "ADE",
              "start_idx": 111,
              "end_idx": 117,
              "entity_en": "Cross allergic reaction"
            },
            {
              "entity_id": "T426",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T427",
              "entity": "肝、肾功能不全",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 49,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T428",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 42,
              "end_idx": 43,
              "entity_en": "liver"
            },
            {
              "entity_id": "T429",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 44,
              "end_idx": 45,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T430",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 102,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T431",
              "entity": "磺胺类药物",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 108,
              "entity_en": "Sulfonamides"
            },
            {
              "entity_id": "T432",
              "entity": "磺胺类药物",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 124,
              "entity_en": "Sulfonamides"
            },
            {
              "entity_id": "T433",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 136,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R158",
              "head_entity_id": "T421",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R159",
              "head_entity_id": "T422",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R160",
              "head_entity_id": "T423",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R161",
              "head_entity_id": "T424",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R162",
              "head_entity_id": "T425",
              "tail_entity_id": "T420"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R163",
              "head_entity_id": "T428",
              "tail_entity_id": "T427"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R164",
              "head_entity_id": "T429",
              "tail_entity_id": "T427"
            }
          ],
          "sentence_en": "Common adverse reactions to sulfonylureas include the following: ① Hypoglycemia: In clinical practice, excessive initial doses of sulfonylureas or inappropriate use in patients with liver or kidney dysfunction can lead to hypoglycemia; hypoglycemia may occur in monotherapy or combined therapy with other hypoglycemic drugs. ② Weight gain. ③ Sulfonylureas and sulfonamides may cause cross-allergic reactions. Sulfonylureas should be contraindicated in patients with a history of allergy to sulfonamides."
        }
      ],
      "paragraph_en": "Common adverse reactions to sulfonylureas include the following: ① Hypoglycemia: In clinical practice, excessive initial doses of sulfonylureas or inappropriate use in patients with liver or kidney dysfunction can lead to hypoglycemia; hypoglycemia may occur in monotherapy or combined therapy with other hypoglycemic drugs. ② Weight gain. ③ Sulfonylureas and sulfonamides may cause cross-allergic reactions. Sulfonylureas should be contraindicated in patients with a history of allergy to sulfonamides."
    },
    {
      "paragraph_id": "49",
      "paragraph": "5.2 如何预防磺脲类药物治疗导致的低血糖? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.2 如何预防磺脲类药物治疗导致的低血糖? ",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T434",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T435",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R165",
              "head_entity_id": "T435",
              "tail_entity_id": "T434"
            }
          ],
          "sentence_en": "5.2 How to prevent hypoglycemia caused by sulfonylurea therapy?"
        }
      ],
      "paragraph_en": "5.2 How to prevent hypoglycemia caused by sulfonylurea therapy?"
    },
    {
      "paragraph_id": "50",
      "paragraph": "荟萃分析结果显示，正确使用磺脲类药物单药及联合治疗的患者，轻、中度低血糖发生率为1.92例/(患者·年)，重度低血糖发生率为0.01例/(患者·年)。不同磺脲类药物的作用机制及剂型存在差异，其低血糖发生率也不同，其中格列本脲导致低血糖的发生风险最高。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "荟萃分析结果显示，正确使用磺脲类药物单药及联合治疗的患者，轻、中度低血糖发生率为1.92例/(患者·年)，重度低血糖发生率为0.01例/(患者·年)。不同磺脲类药物的作用机制及剂型存在差异，其低血糖发生率也不同，其中格列本脲导致低血糖的发生风险最高。",
          "start_idx": 0,
          "end_idx": 125,
          "entities": [
            {
              "entity_id": "T436",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T437",
              "entity": "轻、中度低血糖",
              "entity_type": "ADE",
              "start_idx": 29,
              "end_idx": 36,
              "entity_en": "Mild to moderate hypoglycemia"
            },
            {
              "entity_id": "T438",
              "entity": "重度低血糖",
              "entity_type": "ADE",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "Severe hypoglycemia"
            },
            {
              "entity_id": "T439",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 82,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T440",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 97,
              "end_idx": 99,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T441",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 112,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T442",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 114,
              "end_idx": 117,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R166",
              "head_entity_id": "T437",
              "tail_entity_id": "T436"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R167",
              "head_entity_id": "T438",
              "tail_entity_id": "T436"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R168",
              "head_entity_id": "T442",
              "tail_entity_id": "T441"
            }
          ],
          "sentence_en": "The results of the meta-analysis showed that the incidence of mild and moderate hypoglycemia in patients who correctly used sulfonylureas alone or in combination therapy was 1.92 cases/(patient-year), and the incidence of severe hypoglycemia was 0.01 cases/(patient-year). Different sulfonylureas have different mechanisms of action and dosage forms, and their incidence of hypoglycemia is also different. Among them, glibenclamide has the highest risk of hypoglycemia."
        }
      ],
      "paragraph_en": "The results of the meta-analysis showed that the incidence of mild and moderate hypoglycemia in patients who correctly used sulfonylureas alone or in combination therapy was 1.92 cases/(patient-year), and the incidence of severe hypoglycemia was 0.01 cases/(patient-year). Different sulfonylureas have different mechanisms of action and dosage forms, and their incidence of hypoglycemia is also different. Among them, glibenclamide has the highest risk of hypoglycemia."
    },
    {
      "paragraph_id": "52",
      "paragraph": "5.3 如何看待磺脲类药物增加体重的问题? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.3 如何看待磺脲类药物增加体重的问题? ",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T443",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T444",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Gaining weight"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R169",
              "head_entity_id": "T444",
              "tail_entity_id": "T443"
            }
          ],
          "sentence_en": "5.3 How do you view the issue of weight gain caused by sulfonylureas?"
        }
      ],
      "paragraph_en": "5.3 How do you view the issue of weight gain caused by sulfonylureas?"
    },
    {
      "paragraph_id": "54",
      "paragraph": "5.4 磺脲类药物的心血管安全性如何? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.4 磺脲类药物的心血管安全性如何? ",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T445",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "5.4 What is the cardiovascular safety of sulfonylureas?"
        }
      ],
      "paragraph_en": "5.4 What is the cardiovascular safety of sulfonylureas?"
    },
    {
      "paragraph_id": "55",
      "paragraph": "不同磺脲类药物的心血管安全性可能存在差异。包括UKPDS和ADVANCE等多项大型临床研究结果均证实了磺脲类药物在降糖治疗中的心血管安全性。荟萃分析结果发现，与格列本脲相比，格列齐特和格列美脲可降低T2DM患者的全因死亡风险，而格列吡嗪、甲苯磺丁脲及氯磺丙脲则无此差异。一项为期5年的大样本观察性研究发现，使用格列齐特治疗的患者总病死率和心血管事件死亡率均低于格列本脲，这可能与格列齐特能选择性激活胰岛β细胞的磺脲类受体1(sulfonylurea receptor，SUR1)，而对心肌细胞上的SUR2A和血管平滑肌细胞上的SUR2B无活化作用有关。另外，体外试验证实格列喹酮对胰岛β细胞同样具有高选择性，推测其同样具有较好的心血管安全性。总之，在评价不同磺脲类药物的心血管安全性时，需要具体问题具体分析。磺脲类药物的心血管安全性问题仍需设计优良的前瞻性随机对照研究加以解决。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "不同磺脲类药物的心血管安全性可能存在差异。",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T446",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "The cardiovascular safety of different sulfonylureas may vary."
        },
        {
          "sentence_id": "1",
          "sentence": "包括UKPDS和ADVANCE等多项大型临床研究结果均证实了磺脲类药物在降糖治疗中的心血管安全性。荟萃分析结果发现，与格列本脲相比，格列齐特和格列美脲可降低T2DM患者的全因死亡风险，而格列吡嗪、甲苯磺丁脲及氯磺丙脲则无此差异。一项为期5年的大样本观察性研究发现，使用格列齐特治疗的患者总病死率和心血管事件死亡率均低于格列本脲，这可能与格列齐特能选择性激活胰岛β细胞的磺脲类受体1(sulfonylurea receptor，SUR1)，而对心肌细胞上的SUR2A和血管平滑肌细胞上的SUR2B无活化作用有关。",
          "start_idx": 21,
          "end_idx": 276,
          "entities": [
            {
              "entity_id": "T447",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T448",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T449",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T450",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T451",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 97,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T452",
              "entity": "甲苯磺丁脲",
              "entity_type": "Drug",
              "start_idx": 98,
              "end_idx": 103,
              "entity_en": "Tolbutamide"
            },
            {
              "entity_id": "T453",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T454",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T455",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 159,
              "end_idx": 163,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T456",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 168,
              "end_idx": 172,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T460",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 80,
              "entity_en": "T2"
            },
            {
              "entity_id": "T461",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T462",
              "entity": "心血管事件",
              "entity_type": "ADE",
              "start_idx": 148,
              "end_idx": 153,
              "entity_en": "Cardiovascular events"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R170",
              "head_entity_id": "T449",
              "tail_entity_id": "T461"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R171",
              "head_entity_id": "T450",
              "tail_entity_id": "T461"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R172",
              "head_entity_id": "T462",
              "tail_entity_id": "T454"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R173",
              "head_entity_id": "T462",
              "tail_entity_id": "T455"
            }
          ],
          "sentence_en": "The results of several large clinical studies, including UKPDS and ADVANCE, have confirmed the cardiovascular safety of sulfonylureas in glucose-lowering therapy. Meta-analysis results showed that compared with glibenclamide, gliclazide and glimepiride can reduce the risk of all-cause mortality in patients with T2DM, while glipizide, tolbutamide and chlorpropamide did not show such a difference. A large 5-year observational study found that the total mortality and cardiovascular mortality of patients treated with gliclazide were lower than those with glibenclamide, which may be related to the fact that gliclazide can selectively activate the sulfonylurea receptor 1 (SUR1) of pancreatic β cells, but has no activating effect on SUR2A on cardiomyocytes and SUR2B on vascular smooth muscle cells."
        },
        {
          "sentence_id": "2",
          "sentence": "另外，体外试验证实格列喹酮对胰岛β细胞同样具有高选择性，推测其同样具有较好的心血管安全性。",
          "start_idx": 276,
          "end_idx": 321,
          "entities": [
            {
              "entity_id": "T457",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Gliquidone"
            }
          ],
          "relations": [],
          "sentence_en": "In addition, in vitro experiments have confirmed that gliquidone is also highly selective for pancreatic β cells, and it is speculated that it also has good cardiovascular safety."
        },
        {
          "sentence_id": "3",
          "sentence": "总之，在评价不同磺脲类药物的心血管安全性时，需要具体问题具体分析。",
          "start_idx": 321,
          "end_idx": 354,
          "entities": [
            {
              "entity_id": "T458",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "In short, when evaluating the cardiovascular safety of different sulfonylurea drugs, specific issues need to be analyzed specifically."
        },
        {
          "sentence_id": "4",
          "sentence": "磺脲类药物的心血管安全性问题仍需设计优良的前瞻性随机对照研究加以解决。",
          "start_idx": 354,
          "end_idx": 389,
          "entities": [
            {
              "entity_id": "T459",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "The cardiovascular safety of sulfonylureas still needs to be addressed in well-designed prospective randomized controlled studies."
        }
      ],
      "paragraph_en": "There may be differences in the cardiovascular safety of different sulfonylureas. The results of several large clinical studies, including UKPDS and ADVANCE, have confirmed the cardiovascular safety of sulfonylureas in glucose-lowering treatment. Meta-analysis results found that compared with glibenclamide, gliclazide and glimepiride can reduce the risk of all-cause mortality in patients with T2DM, while glipizide, tolbutamide and chlorpropamide have no such difference. A 5-year large-sample observational study found that the total mortality and cardiovascular mortality of patients treated with gliclazide were lower than those of glibenclamide, which may be related to the fact that gliclazide can selectively activate the sulfonylurea receptor 1 (SUR1) of pancreatic β cells, but has no activating effect on SUR2A on cardiomyocytes and SUR2B on vascular smooth muscle cells. In addition, in vitro experiments have confirmed that gliclazide is also highly selective for pancreatic β cells, and it is speculated that it also has good cardiovascular safety. In short, when evaluating the cardiovascular safety of different sulfonylurea drugs, specific issues need to be analyzed specifically. The cardiovascular safety of sulfonylureas still needs to be addressed in well-designed prospective randomized controlled studies."
    },
    {
      "paragraph_id": "56",
      "paragraph": "5.5 磺脲类药物会加速β细胞功能衰退吗? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.5 磺脲类药物会加速β细胞功能衰退吗? ",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T463",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T464",
              "entity": "β细胞功能衰退",
              "entity_type": "ADE",
              "start_idx": 12,
              "end_idx": 19,
              "entity_en": "β-cell dysfunction"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R174",
              "head_entity_id": "T464",
              "tail_entity_id": "T463"
            }
          ],
          "sentence_en": "5.5 Do sulfonylureas accelerate the decline of β-cell function?"
        }
      ],
      "paragraph_en": "5.5 Do sulfonylureas accelerate the decline of β-cell function?"
    },
    {
      "paragraph_id": "57",
      "paragraph": "β细胞功能凋亡的机制尚未完全明确。持续20年的UKPDS研究结果表明，磺脲类药物并未加速β细胞功能衰竭。ADOPT研究终点时，格列本脲组β细胞胰岛素分泌功能和罗格列酮组相似。中国一项多中心研究结果显示，格列齐特缓释片强化治疗3个月可使约60%的患者血糖达标，停药2日后复查口服葡萄糖耐量试验，恢复为正常糖耐量或糖耐量受损者占22.83%，这说明磺脲类药物强化治疗显著改善了早相胰岛素分泌功能。因此，目前尚无直接证据表明磺脲类药物治疗与β细胞功能衰退有关。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "β细胞功能凋亡的机制尚未完全明确。",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": [],
          "sentence_en": "The mechanism of β-cell functional apoptosis is not yet fully understood."
        },
        {
          "sentence_id": "1",
          "sentence": "持续20年的UKPDS研究结果表明，磺脲类药物并未加速β细胞功能衰竭。ADOPT研究终点时，格列本脲组β细胞胰岛素分泌功能和罗格列酮组相似。中国一项多中心研究结果显示，格列齐特缓释片强化治疗3个月可使约60%的患者血糖达标，停药2日后复查口服葡萄糖耐量试验，恢复为正常糖耐量或糖耐量受损者占22.83%，这说明磺脲类药物强化治疗显著改善了早相胰岛素分泌功能。",
          "start_idx": 17,
          "end_idx": 196,
          "entities": [
            {
              "entity_id": "T465",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T466",
              "entity": "β细胞功能衰竭",
              "entity_type": "Symptom",
              "start_idx": 27,
              "end_idx": 34,
              "entity_en": "β-cell failure"
            },
            {
              "entity_id": "T467",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T468",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Rosiglitazone"
            },
            {
              "entity_id": "T469",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 91,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T470",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 160,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T472",
              "entity": "3个月",
              "entity_type": "Duration",
              "start_idx": 95,
              "end_idx": 98,
              "entity_en": "3 months"
            },
            {
              "entity_id": "T473",
              "entity": "口服葡萄糖耐量试验",
              "entity_type": "Test",
              "start_idx": 119,
              "end_idx": 128,
              "entity_en": "Oral glucose tolerance test"
            },
            {
              "entity_id": "T475",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 107,
              "end_idx": 109,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R175",
              "head_entity_id": "T472",
              "tail_entity_id": "T469"
            }
          ],
          "sentence_en": "The results of the 20-year UKPDS study showed that sulfonylureas did not accelerate β-cell failure. At the end of the ADOPT study, the β-cell insulin secretion function of the glibenclamide group was similar to that of the rosiglitazone group. The results of a multicenter study in China showed that 3 months of intensive treatment with gliclazide extended-release tablets can bring about 60% of patients to standard blood sugar levels. After 2 days of stopping the drug, the oral glucose tolerance test was repeated, and 22.83% of the patients recovered to normal glucose tolerance or impaired glucose tolerance, indicating that intensive treatment with sulfonylureas significantly improved the early phase insulin secretion function."
        },
        {
          "sentence_id": "2",
          "sentence": "因此，目前尚无直接证据表明磺脲类药物治疗与β细胞功能衰退有关。",
          "start_idx": 196,
          "end_idx": 227,
          "entities": [
            {
              "entity_id": "T471",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T474",
              "entity": "β细胞功能衰退",
              "entity_type": "Symptom",
              "start_idx": 21,
              "end_idx": 28,
              "entity_en": "β-cell dysfunction"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, there is currently no direct evidence that sulfonylurea treatment is associated with a decline in β-cell function."
        }
      ],
      "paragraph_en": "The mechanism of β-cell apoptosis has not been fully clarified. The results of the 20-year UKPDS study showed that sulfonylureas did not accelerate β-cell failure. At the end of the ADOPT study, the β-cell insulin secretion function of the glibenclamide group was similar to that of the rosiglitazone group. The results of a multicenter study in China showed that 3 months of intensive treatment with gliclazide extended-release tablets can achieve blood sugar standards in about 60% of patients. After 2 days of stopping the drug, the oral glucose tolerance test was repeated, and 22.83% of the patients recovered to normal glucose tolerance or impaired glucose tolerance. This shows that intensive treatment with sulfonylureas significantly improved the early phase insulin secretion function. Therefore, there is currently no direct evidence that sulfonylurea treatment is related to the decline of β-cell function."
    },
    {
      "paragraph_id": "58",
      "paragraph": "逆向的传导，使患者心肌细胞的自发性兴奋度下降，从而消除折返激动，放慢传导的速度，药效比较持久迅速，但与胺碘酮的治疗效果比较要低一些。胺碘酮作为III类抗心律失常药物，能较为迅速地阻断钾离子的传导通道，从而使心肌兴奋度下降，降低窦房结的自律性，消除折返激动，具有I类和IV类抗心律失常药物的特性，有显著的治疗效果。在本次研究中，治疗组治疗的有效率高于对照组20.93%，并且治疗组血液流变学指标改善较对照组明显，改善后的指标值优于对照组(P<0.05)；治疗组患者服用胺碘酮片后hs-CRP水平明显下降，下降水平同样优于对照组(P<0.05)；治疗组不良反应发生与对照组比较没有较大的差异性(P>0.05)。该研究说明，虽然两种药物的不良反应没有较大差异，但胺碘酮治疗的效果明显优于心律平片，研究结果与学者刘荣魁、许有凡的研究结果基本一致。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "逆向的传导，使患者心肌细胞的自发性兴奋度下降，从而消除折返激动，放慢传导的速度，药效比较持久迅速，但与胺碘酮的治疗效果比较要低一些。",
          "start_idx": 0,
          "end_idx": 66,
          "entities": [
            {
              "entity_id": "T476",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "Amiodarone"
            }
          ],
          "relations": [],
          "sentence_en": "Retrograde conduction reduces the spontaneous excitability of the patient's myocardial cells, thereby eliminating reentrant excitation and slowing down the conduction rate. The drug effect is relatively long-lasting and rapid, but its therapeutic effect is lower than that of amiodarone."
        },
        {
          "sentence_id": "1",
          "sentence": "胺碘酮作为III类抗心律失常药物，能较为迅速地阻断钾离子的传导通道，从而使心肌兴奋度下降，降低窦房结的自律性，消除折返激动，具有I类和IV类抗心律失常药物的特性，有显著的治疗效果。",
          "start_idx": 66,
          "end_idx": 156,
          "entities": [
            {
              "entity_id": "T477",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Amiodarone"
            }
          ],
          "relations": [],
          "sentence_en": "As a Class III antiarrhythmic drug, amiodarone can relatively quickly block the potassium ion conduction channel, thereby reducing myocardial excitability, reducing the autonomy of the sinoatrial node, and eliminating reentrant excitation. It has the characteristics of Class I and Class IV antiarrhythmic drugs and has significant therapeutic effects."
        },
        {
          "sentence_id": "2",
          "sentence": "在本次研究中，治疗组治疗的有效率高于对照组20.93%，并且治疗组血液流变学指标改善较对照组明显，改善后的指标值优于对照组(P<0.05)；治疗组患者服用胺碘酮片后hs-CRP水平明显下降，下降水平同样优于对照组(P<0.05)；治疗组不良反应发生与对照组比较没有较大的差异性(P>0.05)。",
          "start_idx": 156,
          "end_idx": 303,
          "entities": [
            {
              "entity_id": "T478",
              "entity": "胺碘酮片",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 81,
              "entity_en": "Amiodarone Tablets"
            },
            {
              "entity_id": "T481",
              "entity": "hs-CRP",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 88,
              "entity_en": "hs-CRP"
            },
            {
              "entity_id": "T482",
              "entity": "明显下降",
              "entity_type": "Test_Value",
              "start_idx": 90,
              "end_idx": 94,
              "entity_en": "Significant decline"
            }
          ],
          "relations": [],
          "sentence_en": "In this study, the effective rate of the treatment group was 20.93% higher than that of the control group, and the blood rheology indexes of the treatment group were significantly improved compared with those of the control group, and the improved index values were better than those of the control group (P<0.05); the hs-CRP level of the patients in the treatment group decreased significantly after taking amiodarone tablets, and the decrease level was also better than that of the control group (P<0.05); there was no significant difference in the occurrence of adverse reactions between the treatment group and the control group (P>0.05)."
        },
        {
          "sentence_id": "3",
          "sentence": "该研究说明，虽然两种药物的不良反应没有较大差异，但胺碘酮治疗的效果明显优于心律平片，研究结果与学者刘荣魁、许有凡的研究结果基本一致。",
          "start_idx": 303,
          "end_idx": 369,
          "entities": [
            {
              "entity_id": "T479",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "Amiodarone"
            },
            {
              "entity_id": "T480",
              "entity": "心律平片",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "Heart rate tablets"
            }
          ],
          "relations": [],
          "sentence_en": "This study shows that although there is no significant difference in the adverse reactions of the two drugs, the therapeutic effect of amiodarone is significantly better than that of quinidine. The research results are basically consistent with those of scholars Liu Rongkui and Xu Youfan."
        }
      ],
      "paragraph_en": "The reverse conduction reduces the spontaneous excitability of the patient's myocardial cells, thereby eliminating reentrant excitation and slowing down the conduction speed. The drug effect is relatively long-lasting and rapid, but it is lower than the therapeutic effect of amiodarone. As a Class III antiarrhythmic drug, amiodarone can quickly block the conduction channel of potassium ions, thereby reducing myocardial excitability, reducing the autonomy of the sinoatrial node, and eliminating reentrant excitation. It has the characteristics of Class I and Class IV antiarrhythmic drugs and has significant therapeutic effects. In this study, the effective rate of the treatment group was 20.93% higher than that of the control group, and the blood rheology indexes of the treatment group were significantly improved compared with the control group, and the improved index values were better than those of the control group (P<0.05); the hs-CRP level of the patients in the treatment group decreased significantly after taking amiodarone tablets, and the decrease level was also better than that of the control group (P<0.05); there was no significant difference in the occurrence of adverse reactions between the treatment group and the control group (P>0.05). This study shows that although there is no significant difference in the adverse reactions of the two drugs, the therapeutic effect of amiodarone is significantly better than that of quinidine. The research results are basically consistent with those of scholars Liu Rongkui and Xu Youfan."
    },
    {
      "paragraph_id": "59",
      "paragraph": "总之，采用胺碘酮治疗的效果更为显著，明显地改善了患者的血液流变学指标，使hs-CRP水平明显降低，值得临床推广应用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "总之，采用胺碘酮治疗的效果更为显著，明显地改善了患者的血液流变学指标，使hs-CRP水平明显降低，值得临床推广应用。",
          "start_idx": 0,
          "end_idx": 58,
          "entities": [
            {
              "entity_id": "T483",
              "entity": "胺碘酮",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "Amiodarone"
            },
            {
              "entity_id": "T484",
              "entity": "hs-CRP",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 42,
              "entity_en": "hs-CRP"
            },
            {
              "entity_id": "T485",
              "entity": "明显降低",
              "entity_type": "Test_Value",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Significantly reduced"
            }
          ],
          "relations": [],
          "sentence_en": "In short, the effect of amiodarone treatment is more significant, which significantly improves the patient's blood rheology indicators and significantly reduces the hs-CRP level, and is worthy of clinical promotion and application."
        }
      ],
      "paragraph_en": "In short, the effect of amiodarone treatment is more significant, which significantly improves the patient's blood rheology indicators and significantly reduces the hs-CRP level, and is worthy of clinical promotion and application."
    },
    {
      "paragraph_id": "53",
      "paragraph": "目前普遍认为长期使用磺脲类药物可致患者体重明显增加，但不同磺脲类药物对体重的影响存在差异。剂型改良后的磺脲类药物及格列美脲对体重影响较小。随机对照研究结果显示，2型糖尿病患者使用格列吡嗪单药治疗1年体重增加2.6kg。GUIDE研究中随机分为格列齐特缓释片组和格列美脲组治疗27周，体重增加分别为0.5kg和0.6kg。荟萃分析结果显示，磺脲类药物单药治疗平均约增加体重2kg，但磺脲类药物与二甲双胍、SGLT-2抑制剂、GLP-1受体激动剂等药物联合时，这一不良反应可能会被完全或部分抵消。ZODIAC-39队列研究显示，不同磺脲类药物联合二甲双胍治疗5年，格列本脲组体重增加3.3kg，格列齐特组体重增加3.9kg，格列美脲组体重增加0.1kg。LEAD-1研究显示，之前使用格列美脲单药治疗的T2DM患者换为格列美脲联合利拉鲁肽1.2mg/d或1.8mg/d治疗后，体重变化分别为+0.3kg和-0.2kg。格列美脲单药治疗血糖控制不佳的患者，加用达格列净后不仅可以进一步改善血糖，还可改善体重。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前普遍认为长期使用磺脲类药物可致患者体重明显增加，但不同磺脲类药物对体重的影响存在差异。剂型改良后的磺脲类药物及格列美脲对体重影响较小。随机对照研究结果显示，2型糖尿病患者使用格列吡嗪单药治疗1年体重增加2.6kg。GUIDE研究中随机分为格列齐特缓释片组和格列美脲组治疗27周，体重增加分别为0.5kg和0.6kg。荟萃分析结果显示，磺脲类药物单药治疗平均约增加体重2kg，但磺脲类药物与二甲双胍、SGLT-2抑制剂、GLP-1受体激动剂等药物联合时，这一不良反应可能会被完全或部分抵消。ZODIAC-39队列研究显示，不同磺脲类药物联合二甲双胍治疗5年，格列本脲组体重增加3.3kg，格列齐特组体重增加3.9kg，格列美脲组体重增加0.1kg。LEAD-1研究显示，之前使用格列美脲单药治疗的T2DM患者换为格列美脲联合利拉鲁肽1.2mg/d或1.8mg/d治疗后，体重变化分别为+0.3kg和-0.2kg。",
          "start_idx": 0,
          "end_idx": 407,
          "entities": [
            {
              "entity_id": "T486",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T487",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T488",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 56,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T489",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T490",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T491",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 128,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T492",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T493",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 174,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T494",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 195,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T495",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 196,
              "end_idx": 200,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T496",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 201,
              "end_idx": 210,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T497",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 221,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T498",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 264,
              "end_idx": 269,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T499",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 271,
              "end_idx": 275,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T500",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 280,
              "end_idx": 284,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T501",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 295,
              "end_idx": 299,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T502",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 310,
              "end_idx": 314,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T503",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 340,
              "end_idx": 344,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T504",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 357,
              "end_idx": 361,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T505",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 363,
              "end_idx": 367,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T508",
              "entity": "体重明显增加",
              "entity_type": "ADE",
              "start_idx": 19,
              "end_idx": 25,
              "entity_en": "Significant weight gain"
            },
            {
              "entity_id": "T509",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T510",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 80,
              "end_idx": 85,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T511",
              "entity": "1年",
              "entity_type": "Duration",
              "start_idx": 97,
              "end_idx": 99,
              "entity_en": "1 year"
            },
            {
              "entity_id": "T512",
              "entity": "27周",
              "entity_type": "Duration",
              "start_idx": 137,
              "end_idx": 140,
              "entity_en": "27 weeks"
            },
            {
              "entity_id": "T513",
              "entity": "5年",
              "entity_type": "Duration",
              "start_idx": 277,
              "end_idx": 279,
              "entity_en": "5 years"
            },
            {
              "entity_id": "T514",
              "entity": "1.2mg/d",
              "entity_type": "Amount",
              "start_idx": 367,
              "end_idx": 374,
              "entity_en": "1.2 mg/day"
            },
            {
              "entity_id": "T515",
              "entity": "1.8mg/d",
              "entity_type": "Amount",
              "start_idx": 375,
              "end_idx": 382,
              "entity_en": "1.8 mg/day"
            },
            {
              "entity_id": "T516",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 349,
              "end_idx": 351,
              "entity_en": "T2"
            },
            {
              "entity_id": "T517",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 349,
              "end_idx": 353,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T520",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T521",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 141,
              "end_idx": 145,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T522",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 181,
              "end_idx": 185,
              "entity_en": "Gaining weight"
            },
            {
              "entity_id": "T523",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 285,
              "end_idx": 289,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T524",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 300,
              "end_idx": 304,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T525",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 315,
              "end_idx": 319,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R176",
              "head_entity_id": "T508",
              "tail_entity_id": "T486"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R177",
              "head_entity_id": "T520",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R178",
              "head_entity_id": "T511",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R179",
              "head_entity_id": "T490",
              "tail_entity_id": "T510"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R180",
              "head_entity_id": "T521",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R181",
              "head_entity_id": "T512",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R182",
              "head_entity_id": "T521",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R183",
              "head_entity_id": "T512",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R184",
              "head_entity_id": "T522",
              "tail_entity_id": "T493"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R185",
              "head_entity_id": "T513",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R186",
              "head_entity_id": "T513",
              "tail_entity_id": "T499"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R187",
              "head_entity_id": "T523",
              "tail_entity_id": "T500"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R188",
              "head_entity_id": "T524",
              "tail_entity_id": "T501"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R189",
              "head_entity_id": "T525",
              "tail_entity_id": "T502"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T504",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R191",
              "head_entity_id": "T514",
              "tail_entity_id": "T505"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R192",
              "head_entity_id": "T515",
              "tail_entity_id": "T505"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R193",
              "head_entity_id": "T505",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R194",
              "head_entity_id": "T509",
              "tail_entity_id": "T510"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R195",
              "head_entity_id": "T516",
              "tail_entity_id": "T517"
            }
          ],
          "sentence_en": "It is generally believed that long-term use of sulfonylureas can cause patients to gain significant weight, but the effects of different sulfonylureas on body weight vary. The modified dosage forms of sulfonylureas and glimepiride have little effect on body weight. The results of randomized controlled studies showed that patients with type 2 diabetes gained 2.6 kg in weight after one year of treatment with glipizide alone. In the GUIDE study, patients were randomly divided into the gliclazide sustained-release tablet group and the glimepiride group for 27 weeks of treatment, with weight gains of 0.5 kg and 0.6 kg, respectively. The results of meta-analysis showed that sulfonylurea monotherapy increased body weight by an average of about 2 kg, but this adverse reaction may be completely or partially offset when sulfonylureas are combined with metformin, SGLT-2 inhibitors, GLP-1 receptor agonists and other drugs. The ZODIAC-39 cohort study showed that after 5 years of treatment with different sulfonylureas combined with metformin, the glibenclamide group gained 3.3 kg in weight, the gliclazide group gained 3.9 kg in weight, and the glimepiride group gained 0.1 kg in weight. The LEAD-1 study showed that after T2DM patients who were previously treated with glimepiride alone switched to glimepiride combined with liraglutide 1.2 mg/d or 1.8 mg/d, their weight changes were +0.3 kg and -0.2 kg, respectively."
        },
        {
          "sentence_id": "1",
          "sentence": "格列美脲单药治疗血糖控制不佳的患者，加用达格列净后不仅可以进一步改善血糖，还可改善体重。",
          "start_idx": 407,
          "end_idx": 451,
          "entities": [
            {
              "entity_id": "T506",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T507",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T518",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T519",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "For patients with poor blood sugar control on glimepiride monotherapy, adding dapagliflozin can not only further improve blood sugar but also improve body weight."
        }
      ],
      "paragraph_en": "It is generally believed that long-term use of sulfonylureas can cause patients to gain significant weight, but the effects of different sulfonylureas on body weight vary. The modified dosage forms of sulfonylureas and glimepiride have little effect on body weight. The results of randomized controlled studies showed that patients with type 2 diabetes gained 2.6 kg in weight after one year of treatment with glipizide alone. In the GUIDE study, patients were randomly divided into the gliclazide sustained-release tablet group and the glimepiride group for 27 weeks of treatment, with weight gains of 0.5 kg and 0.6 kg, respectively. The results of meta-analysis showed that sulfonylurea monotherapy increased body weight by an average of about 2 kg, but this adverse reaction may be completely or partially offset when sulfonylureas are combined with metformin, SGLT-2 inhibitors, GLP-1 receptor agonists and other drugs. The ZODIAC-39 cohort study showed that after 5 years of treatment with different sulfonylureas combined with metformin, the glibenclamide group gained 3.3 kg in weight, the gliclazide group gained 3.9 kg in weight, and the glimepiride group gained 0.1 kg in weight. The LEAD-1 study showed that the weight changes of T2DM patients who were previously treated with glimepiride alone and switched to glimepiride combined with liraglutide 1.2mg/d or 1.8mg/d were +0.3kg and -0.2kg, respectively. For patients with poor blood sugar control on glimepiride alone, the addition of dapagliflozin can not only further improve blood sugar, but also improve weight."
    },
    {
      "paragraph_id": "51",
      "paragraph": "增加磺脲类药物发生低血糖事件的主要因素有：高龄，饮酒，合并肝、肾疾病，药物过量，药物相互作用等。糖尿病患者在使用磺脲类药物时，预防低血糖的措施包括：①年长、体弱的患者建议选用低血糖风险相对低的格列齐特缓释片、格列美脲，或者其他短效制剂；2应从小剂量开始服用，并根据血糖监测结果缓慢加量至最佳剂量；③饮食方面应定食定量，避免餐前剧烈运动。如果出现腹泻、呕吐等症状，应减少药物剂量；④每天的运动量应保持相对稳定。运动量过大也可引起低血糖，在外出旅游、登山时，应适量增加饮食。对于绝大多数可被患者察觉的、有症状的低血糖事件，可通过补充含糖食物或口服/静脉推注20g葡萄糖予以纠正，若15~20min后症状仍不能缓解或血浆葡萄糖水平仍很低可以重复给予葡萄糖。对于发生严重低血糖事件的患者，尤其格列本脲所致者，需在静脉推注葡萄糖后给予较长时间(24~72h)的葡萄糖静脉滴注以防止低血糖的再次发生，并至少观察3d，密切监测血糖水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "增加磺脲类药物发生低血糖事件的主要因素有：高龄，饮酒，合并肝、肾疾病，药物过量，药物相互作用等。糖尿病患者在使用磺脲类药物时，预防低血糖的措施包括：①年长、体弱的患者建议选用低血糖风险相对低的格列齐特缓释片、格列美脲，或者其他短效制剂；2应从小剂量开始服用，并根据血糖监测结果缓慢加量至最佳剂量；③饮食方面应定食定量，避免餐前剧烈运动。如果出现腹泻、呕吐等症状，应减少药物剂量；④每天的运动量应保持相对稳定。运动量过大也可引起低血糖，在外出旅游、登山时，应适量增加饮食。对于绝大多数可被患者察觉的、有症状的低血糖事件，可通过补充含糖食物或口服/静脉推注20g葡萄糖予以纠正，若15~20min后症状仍不能缓解或血浆葡萄糖水平仍很低可以重复给予葡萄糖。对于发生严重低血糖事件的患者，尤其格列本脲所致者，需在静脉推注葡萄糖后给予较长时间(24~72h)的葡萄糖静脉滴注以防止低血糖的再次发生，并至少观察3d，密切监测血糖水平。",
          "start_idx": 0,
          "end_idx": 411,
          "entities": [
            {
              "entity_id": "T526",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T527",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T528",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T529",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 61,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T530",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T531",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 87,
              "end_idx": 90,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T532",
              "entity": "格列齐特缓释片",
              "entity_type": "Drug",
              "start_idx": 96,
              "end_idx": 103,
              "entity_en": "Gliclazide extended-release tablets"
            },
            {
              "entity_id": "T533",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T534",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 132,
              "end_idx": 134,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T535",
              "entity": "腹泻",
              "entity_type": "ADE",
              "start_idx": 172,
              "end_idx": 174,
              "entity_en": "diarrhea"
            },
            {
              "entity_id": "T536",
              "entity": "呕吐",
              "entity_type": "ADE",
              "start_idx": 175,
              "end_idx": 177,
              "entity_en": "Vomit"
            },
            {
              "entity_id": "T537",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 213,
              "end_idx": 216,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T538",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 253,
              "end_idx": 256,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T539",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 269,
              "end_idx": 271,
              "entity_en": "oral"
            },
            {
              "entity_id": "T540",
              "entity": "静脉推注",
              "entity_type": "Method",
              "start_idx": 272,
              "end_idx": 276,
              "entity_en": "IV push"
            },
            {
              "entity_id": "T541",
              "entity": "20g",
              "entity_type": "Amount",
              "start_idx": 276,
              "end_idx": 279,
              "entity_en": "20g"
            },
            {
              "entity_id": "T542",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 282,
              "entity_en": "glucose"
            },
            {
              "entity_id": "T543",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 321,
              "end_idx": 324,
              "entity_en": "glucose"
            },
            {
              "entity_id": "T544",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 331,
              "end_idx": 334,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T545",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 342,
              "end_idx": 346,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T546",
              "entity": "静脉推注",
              "entity_type": "Method",
              "start_idx": 352,
              "end_idx": 356,
              "entity_en": "IV push"
            },
            {
              "entity_id": "T547",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 356,
              "end_idx": 359,
              "entity_en": "glucose"
            },
            {
              "entity_id": "T548",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 375,
              "end_idx": 378,
              "entity_en": "glucose"
            },
            {
              "entity_id": "T549",
              "entity": "静脉滴注",
              "entity_type": "Method",
              "start_idx": 378,
              "end_idx": 382,
              "entity_en": "Intravenous drip"
            },
            {
              "entity_id": "T550",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 385,
              "end_idx": 388,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T551",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 406,
              "end_idx": 408,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R196",
              "head_entity_id": "T527",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R197",
              "head_entity_id": "T535",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R198",
              "head_entity_id": "T536",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R199",
              "head_entity_id": "T537",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R200",
              "head_entity_id": "T538",
              "tail_entity_id": "T526"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R201",
              "head_entity_id": "T534",
              "tail_entity_id": "T528"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R202",
              "head_entity_id": "T530",
              "tail_entity_id": "T529"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R203",
              "head_entity_id": "T531",
              "tail_entity_id": "T532"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R204",
              "head_entity_id": "T531",
              "tail_entity_id": "T533"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R205",
              "head_entity_id": "T539",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R206",
              "head_entity_id": "T540",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R207",
              "head_entity_id": "T541",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R208",
              "head_entity_id": "T544",
              "tail_entity_id": "T545"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R209",
              "head_entity_id": "T550",
              "tail_entity_id": "T545"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R210",
              "head_entity_id": "T546",
              "tail_entity_id": "T547"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R211",
              "head_entity_id": "T549",
              "tail_entity_id": "T548"
            }
          ],
          "sentence_en": "The main factors that increase the incidence of hypoglycemia with sulfonylureas include: advanced age, drinking, liver and kidney diseases, drug overdose, drug interactions, etc. When using sulfonylureas, diabetic patients should take measures to prevent hypoglycemia: ① Elderly and frail patients are advised to use gliclazide sustained-release tablets, glimepiride, or other short-acting preparations with relatively low risk of hypoglycemia; 2 It should be taken from a small dose and slowly increased to the optimal dose according to the results of blood glucose monitoring; ③ The diet should be fixed and quantitative, and strenuous exercise before meals should be avoided. If symptoms such as diarrhea and vomiting occur, the drug dose should be reduced; ④ The amount of exercise per day should be kept relatively stable. Excessive exercise can also cause hypoglycemia. When traveling or climbing, the diet should be increased appropriately. For most symptomatic hypoglycemia events that can be detected by patients, they can be corrected by supplementing sugary foods or oral/intravenous injection of 20g of glucose. If the symptoms are still not relieved after 15-20 minutes or the plasma glucose level is still very low, glucose can be given repeatedly. For patients who have severe hypoglycemia, especially those caused by glibenclamide, it is necessary to give glucose intravenous drip for a longer period of time (24-72 hours) after intravenous glucose push to prevent the recurrence of hypoglycemia, and observe for at least 3 days and closely monitor blood glucose levels."
        }
      ],
      "paragraph_en": "The main factors that increase the incidence of hypoglycemia with sulfonylureas include: advanced age, drinking, liver and kidney diseases, drug overdose, drug interactions, etc. When using sulfonylureas, diabetic patients should take measures to prevent hypoglycemia: ① Elderly and frail patients are advised to use gliclazide sustained-release tablets, glimepiride, or other short-acting preparations with relatively low risk of hypoglycemia; 2 It should be taken from a small dose and slowly increased to the optimal dose according to the results of blood glucose monitoring; ③ The diet should be fixed and quantitative, and strenuous exercise before meals should be avoided. If symptoms such as diarrhea and vomiting occur, the drug dose should be reduced; ④ The amount of exercise per day should be kept relatively stable. Excessive exercise can also cause hypoglycemia. When traveling or climbing, the diet should be increased appropriately. For most symptomatic hypoglycemia events that can be detected by patients, they can be corrected by supplementing sugary foods or oral/intravenous injection of 20g of glucose. If the symptoms are still not relieved after 15-20 minutes or the plasma glucose level is still very low, glucose can be given repeatedly. For patients who have severe hypoglycemia, especially those caused by glibenclamide, it is necessary to give glucose intravenous drip for a longer period of time (24-72 hours) after intravenous glucose push to prevent the recurrence of hypoglycemia, and observe for at least 3 days and closely monitor blood glucose levels."
    },
    {
      "paragraph_id": "5",
      "paragraph": "2013年版《中国2型糖尿病防治指南》推荐磺脲类药物为重要的一线备选和二线降糖药物，可作为二甲双胍不耐受或存在禁忌证者的起始治疗或二甲双胍治疗血糖控制不佳时的联合用药之一。2014年国际糖尿病联盟(International Diabetes Federation，IDF)全球T2DM指南同样将磺脲类药物作为不适合二甲双胍治疗的患者的一线备选和二线首选药物。2016年美国临床内分泌医师协会(American Association of Clinical Endocrinologists，AACE)和美国内分泌学会(American College of Endocrinology，ACE)指南将磺脲类药物列为T2DM的一线治疗药物之一，但给予谨慎使用的标识。2016年美国糖尿病学会(American Diabetes Association，ADA)指南则推荐磺脲类药物为T2DM患者二甲双胍治疗后的二线药物。因此，磺脲类药物目前仍是临床上治疗T2DM的常用口服药物之一，具有相当重要的临床地位。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2013年版《中国2型糖尿病防治指南》推荐磺脲类药物为重要的一线备选和二线降糖药物，可作为二甲双胍不耐受或存在禁忌证者的起始治疗或二甲双胍治疗血糖控制不佳时的联合用药之一。2014年国际糖尿病联盟(International Diabetes Federation，IDF)全球T2DM指南同样将磺脲类药物作为不适合二甲双胍治疗的患者的一线备选和二线首选药物。2016年美国临床内分泌医师协会(American Association of Clinical Endocrinologists，AACE)和美国内分泌学会(American College of Endocrinology，ACE)指南将磺脲类药物列为T2DM的一线治疗药物之一，但给予谨慎使用的标识。2016年美国糖尿病学会(American Diabetes Association，ADA)指南则推荐磺脲类药物为T2DM患者二甲双胍治疗后的二线药物。因此，磺脲类药物目前仍是临床上治疗T2DM的常用口服药物之一，具有相当重要的临床地位。",
          "start_idx": 0,
          "end_idx": 454,
          "entities": [
            {
              "entity_id": "T552",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 26,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T553",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T554",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 69,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T555",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 148,
              "end_idx": 153,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T556",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 162,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T557",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 302,
              "end_idx": 307,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T558",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 386,
              "end_idx": 391,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T559",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 398,
              "end_idx": 402,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T560",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 414,
              "end_idx": 419,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T561",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T562",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 93,
              "end_idx": 96,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T563",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 341,
              "end_idx": 344,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T564",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T565",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T566",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 435,
              "end_idx": 437,
              "entity_en": "oral"
            },
            {
              "entity_id": "T567",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 139,
              "end_idx": 141,
              "entity_en": "T2"
            },
            {
              "entity_id": "T568",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 143,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T569",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 309,
              "end_idx": 311,
              "entity_en": "T2"
            },
            {
              "entity_id": "T570",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 309,
              "end_idx": 313,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T571",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 428,
              "end_idx": 430,
              "entity_en": "T2"
            },
            {
              "entity_id": "T572",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 428,
              "end_idx": 432,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T573",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 392,
              "end_idx": 394,
              "entity_en": "T2"
            },
            {
              "entity_id": "T574",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 392,
              "end_idx": 396,
              "entity_en": "T2DM"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R212",
              "head_entity_id": "T552",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R213",
              "head_entity_id": "T553",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R214",
              "head_entity_id": "T554",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R215",
              "head_entity_id": "T555",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R216",
              "head_entity_id": "T557",
              "tail_entity_id": "T570"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R217",
              "head_entity_id": "T558",
              "tail_entity_id": "T574"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R218",
              "head_entity_id": "T559",
              "tail_entity_id": "T574"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T560",
              "tail_entity_id": "T572"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R220",
              "head_entity_id": "T566",
              "tail_entity_id": "T560"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R221",
              "head_entity_id": "T564",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R222",
              "head_entity_id": "T565",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R223",
              "head_entity_id": "T569",
              "tail_entity_id": "T570"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R224",
              "head_entity_id": "T573",
              "tail_entity_id": "T574"
            }
          ],
          "sentence_en": "The 2013 edition of the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China recommends sulfonylureas as important first-line alternatives and second-line hypoglycemic drugs, which can be used as the initial treatment for patients who are intolerant to metformin or have contraindications, or as one of the combination drugs when metformin treatment does not control blood sugar well. The 2014 International Diabetes Federation (IDF) Global T2DM Guidelines also list sulfonylureas as first-line alternatives and second-line preferred drugs for patients who are not suitable for metformin treatment. The 2016 guidelines of the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) list sulfonylureas as one of the first-line treatment drugs for T2DM, but give a label for cautious use. The 2016 guidelines of the American Diabetes Association (ADA) recommend sulfonylureas as second-line drugs after metformin treatment for patients with T2DM. Therefore, sulfonylureas are still one of the commonly used oral drugs for the clinical treatment of T2DM and have a very important clinical position."
        }
      ],
      "paragraph_en": "The 2013 edition of the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China recommends sulfonylureas as important first-line alternatives and second-line hypoglycemic drugs, which can be used as the initial treatment for patients who are intolerant to metformin or have contraindications, or as one of the combination drugs when metformin treatment does not control blood sugar well. The 2014 International Diabetes Federation (IDF) Global T2DM Guidelines also list sulfonylureas as first-line alternatives and second-line preferred drugs for patients who are not suitable for metformin treatment. The 2016 guidelines of the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) list sulfonylureas as one of the first-line treatment drugs for T2DM, but give a label for cautious use. The 2016 guidelines of the American Diabetes Association (ADA) recommend sulfonylureas as second-line drugs after metformin treatment for patients with T2DM. Therefore, sulfonylureas are still one of the commonly used oral drugs for the clinical treatment of T2DM and have a very important clinical position."
    },
    {
      "paragraph_id": "1",
      "paragraph": "磺脲类药物仍是目前糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病(type 2 diabetes mellitus，T2DM)指南中占据着非常重要的治疗地位。长期的临床应用和大量的循证医学证据均表明，磺脲类药物不仅降糖作用强，还可减少或延缓T2DM慢性并发症的发生，特别是微血管并发症。不同磺脲类药物的分子结构、药代/药效动力学以及剂型存在差异，其疗效和安全性也有所不同。为进一步提高临床医生对磺脲类药物的认识，更好地指导临床合理用药，内分泌专家基于循证医学证据的进展，对2004年版《磺脲类药物临床应用专家共识》进行了更新。新版共识采用问答的形式阐明了当前磺脲类药物的临床地位、作用机制、疗效、安全性以及特殊人群用药等问题。主要推荐意见见表1。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类药物仍是目前糖尿病治疗领域应用最为广泛的口服降糖药物之一，并且在国内外2型糖尿病(type 2 diabetes mellitus，T2DM)指南中占据着非常重要的治疗地位。长期的临床应用和大量的循证医学证据均表明，磺脲类药物不仅降糖作用强，还可减少或延缓T2DM慢性并发症的发生，特别是微血管并发症。",
          "start_idx": 0,
          "end_idx": 154,
          "entities": [
            {
              "entity_id": "T575",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T576",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T577",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 116,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T581",
              "entity": "微血管并发症",
              "entity_type": "Disease",
              "start_idx": 147,
              "end_idx": 153,
              "entity_en": "Microvascular complications"
            },
            {
              "entity_id": "T582",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 147,
              "end_idx": 150,
              "entity_en": "Microvascular"
            },
            {
              "entity_id": "T584",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 131,
              "end_idx": 133,
              "entity_en": "T2"
            },
            {
              "entity_id": "T585",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 135,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T586",
              "entity": "2型糖尿病(type 2 diabetes mellitus，T2DM)",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 74,
              "entity_en": "Type 2 diabetes mellitus (T2DM)"
            },
            {
              "entity_id": "T587",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 38,
              "end_idx": 40,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R225",
              "head_entity_id": "T576",
              "tail_entity_id": "T575"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R226",
              "head_entity_id": "T577",
              "tail_entity_id": "T585"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R227",
              "head_entity_id": "T582",
              "tail_entity_id": "T581"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R228",
              "head_entity_id": "T584",
              "tail_entity_id": "T585"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R229",
              "head_entity_id": "T587",
              "tail_entity_id": "T586"
            }
          ],
          "sentence_en": "Sulfonylureas are still one of the most widely used oral glucose-lowering drugs in the field of diabetes treatment, and they occupy a very important treatment position in the type 2 diabetes mellitus (T2DM) guidelines at home and abroad. Long-term clinical application and a large amount of evidence-based medicine have shown that sulfonylureas not only have a strong glucose-lowering effect, but also can reduce or delay the occurrence of chronic complications of T2DM, especially microvascular complications."
        },
        {
          "sentence_id": "1",
          "sentence": "不同磺脲类药物的分子结构、药代/药效动力学以及剂型存在差异，其疗效和安全性也有所不同。",
          "start_idx": 154,
          "end_idx": 197,
          "entities": [
            {
              "entity_id": "T578",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "Different sulfonylurea drugs differ in their molecular structure, pharmacokinetics/pharmacodynamics, and dosage forms, and their efficacy and safety also vary."
        },
        {
          "sentence_id": "2",
          "sentence": "为进一步提高临床医生对磺脲类药物的认识，更好地指导临床合理用药，内分泌专家基于循证医学证据的进展，对2004年版《磺脲类药物临床应用专家共识》进行了更新。",
          "start_idx": 197,
          "end_idx": 274,
          "entities": [
            {
              "entity_id": "T579",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T583",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 62,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "In order to further improve clinicians' understanding of sulfonylureas and better guide rational clinical drug use, endocrinologists updated the 2004 edition of \"Expert Consensus on the Clinical Application of Sulfonylureas\" based on the progress of evidence-based medicine."
        },
        {
          "sentence_id": "3",
          "sentence": "新版共识采用问答的形式阐明了当前磺脲类药物的临床地位、作用机制、疗效、安全性以及特殊人群用药等问题。",
          "start_idx": 274,
          "end_idx": 324,
          "entities": [
            {
              "entity_id": "T580",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 21,
              "entity_en": "Sulfonylureas"
            }
          ],
          "relations": [],
          "sentence_en": "The new consensus uses a question-and-answer format to explain the current clinical status, mechanism of action, efficacy, safety, and use of sulfonylurea drugs in special populations."
        },
        {
          "sentence_id": "4",
          "sentence": "主要推荐意见见表1。",
          "start_idx": 324,
          "end_idx": 334,
          "entities": [],
          "relations": [],
          "sentence_en": "The main recommendations are shown in Table 1."
        }
      ],
      "paragraph_en": "Sulfonylureas are still one of the most widely used oral hypoglycemic drugs in the treatment of diabetes and occupy a very important therapeutic position in the guidelines for type 2 diabetes mellitus (T2DM) at home and abroad. Long-term clinical application and a large amount of evidence-based medicine have shown that sulfonylureas not only have a strong hypoglycemic effect, but also can reduce or delay the occurrence of chronic complications of T2DM, especially microvascular complications. Different sulfonylureas have different molecular structures, pharmacokinetics/pharmacodynamics, and dosage forms, and their efficacy and safety are also different. In order to further improve clinicians' understanding of sulfonylureas and better guide clinical rational drug use, endocrine experts have updated the 2004 version of the \"Expert Consensus on the Clinical Application of Sulfonylureas\" based on the progress of evidence-based medicine. The new consensus uses a question-and-answer format to explain the current clinical status, mechanism of action, efficacy, safety, and medication for special populations of sulfonylureas. The main recommendations are shown in Table 1."
    }
  ]
}